;;;year
Bayesian Simulation Model (MDACC);Huang X, Li Y, Song J, Berry DA, A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28627297;2018
Bayesian Simulation Model (MDACC);Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK, et al., Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554466;2018
Bayesian Simulation Model (MDACC);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, et al., Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554468;2018
Bayesian Simulation Model (MDACC);Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554472;2018
Bayesian Simulation Model (MDACC);Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, et al., Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012, JAMA, Jan. 9, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29318276;2018
BCOS (Stanford);Munoz DF, Plevritis SK, Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554464;2018
BCOS (Stanford);Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK, et al., Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554466;2018
BCOS (Stanford);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, et al., Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554468;2018
BCOS (Stanford);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, et al., Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554471;2018
BCOS (Stanford);Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554472;2018
BCOS (Stanford);Munoz DF, Xu C, Plevritis SK, A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554473;2018
BCOS (Stanford);Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, et al., Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012, JAMA, Jan. 9, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29318276;2018
CISNET-DFCI (Dana-Farber);Lee SJ, Li X, Huang H, Zelen M, The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554465;2018
CISNET-DFCI (Dana-Farber);Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK, et al., Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554466;2018
CISNET-DFCI (Dana-Farber);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, et al., Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554468;2018
CISNET-DFCI (Dana-Farber);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, et al., Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554471;2018
CISNET-DFCI (Dana-Farber);Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554472;2018
CISNET-DFCI (Dana-Farber);Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, et al., Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012, JAMA, Jan. 9, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29318276;2018
MISCAN-Fadia (Erasmus);Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK, et al., Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554466;2018
MISCAN-Fadia (Erasmus);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, et al., Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554468;2018
MISCAN-Fadia (Erasmus);van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ, Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554469;2018
MISCAN-Fadia (Erasmus);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, et al., Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554471;2018
MISCAN-Fadia (Erasmus);Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554472;2018
MISCAN-Fadia (Erasmus);Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, et al., Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012, JAMA, Jan. 9, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29318276;2018
Spectrum/G-E (Georgetown/Einstein);Schechter CB, Near AM, Jayasekera J, Chandler Y, Mandelblatt JS, Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554462;2018
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK, et al., Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554466;2018
Spectrum/G-E (Georgetown/Einstein);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, et al., Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554471;2018
Spectrum/G-E (Georgetown/Einstein);Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554472;2018
Spectrum/G-E (Georgetown/Einstein);Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, et al., Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012, JAMA, Jan. 9, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29318276;2018
UWBCS (Wisconsin);Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK, et al., Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554466;2018
UWBCS (Wisconsin);Gangnon RE, Stout NK, Alagoz O, Hampton JM, Sprague BL, Trentham-Dietz A, Contribution of Breast Cancer to Overall Mortality for US Women, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554467;2018
UWBCS (Wisconsin);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, et al., Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554468;2018
UWBCS (Wisconsin);Alagoz O, Ergun MA, Cevik M, Sprague BL, Fryback DG, Gangnon RE, Hampton JM, Stout NK, Trentham-Dietz A, The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554470;2018
UWBCS (Wisconsin);van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, et al., Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554471;2018
UWBCS (Wisconsin);Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models, Med Decis Making, April 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29554472;2018
UWBCS (Wisconsin);Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, et al., Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012, JAMA, Jan. 9, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29318276;2018
MISCAN-Colon (Erasmus/MSK);Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations, Gastroenterology, Feb. 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29289528;2018
MISCAN-Colon (Erasmus/MSK);Naber SK, Kuntz KM, Henrikson NB, Williams MS, Calonge N, Goddard KAB, Zallen DT, Ganiats TG, Webber EM, Janssens ACJW, van Ballegooijen M, et al., Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer, Gastroenterology, Jan. 1, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28964749;2018
MISCAN-PRO (Erasmus);de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, et al., The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials, Cancer, March 15, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29211316;2018
PSAPC (FHCRC);de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, et al., The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials, Cancer, March 15, 2018 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29211316;2018
Spectrum/G-E (Georgetown/Einstein);Lieu TA, Ray GT, Prausnitz SR, Habel LA, Alexeeff S, Li Y, Ramsey SD, Phelps CE, Chawla N, C O'Neill S, Mandelblatt JS, et al., Oncologist and organizational factors associated with variation in breast cancer multigene testing, Breast Cancer Res Treat, May 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28224383;2017
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE, Evaluating Frameworks That Provide Value Measures for Health Care Interventions, Value Health, Feb. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28237193;2017
UWBCS (Wisconsin);Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, et al., Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study, Cancer Epidemiol Biomarkers Prev, Nov. 17, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29150480;2017
HSPH-Cervical (Harvard);Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, et al., Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study, Cancer Epidemiol Biomarkers Prev, Nov. 17, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29150480;2017
Policy1-Cervix (CCNSW);Velentzis LS, Caruana M, Simms KT, Lew JB, Shi JF, Saville M, Smith MA, Lord SJ, Tan J, Bateson D, Quinn M, et al., How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country, Int J Cancer, Dec. 15, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28801947;2017
Policy1-Cervix (CCNSW);Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, Caruana M, Velentzis LS, Bessell T, Saville M, Hammond I, et al., Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program, Lancet Public Health, Feb. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29253402;2017
Policy1-Cervix (CCNSW);Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, Hammond I, Saville M, Canfell K, Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia, PLoS One, Jan. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28095411;2017
CRC-SPIN (RAND);Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, et al., Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study, Cancer Epidemiol Biomarkers Prev, Nov. 17, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29150480;2017
MISCAN-Colon (Erasmus/MSK);Meester RGS, Doubeni CA, Zauber AG, van Ballegooijen M, Corley DA, Lansdorp-Vogelaar I, Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer, Int J Cancer, Dec. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28815573;2017
MISCAN-Colon (Erasmus/MSK);Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I, Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries, Health Aff (Millwood), Dec. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29200350;2017
MISCAN-Colon (Erasmus/MSK);Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, et al., Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study, Cancer Epidemiol Biomarkers Prev, Nov. 17, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29150480;2017
MISCAN-Colon (Erasmus/MSK);Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I, Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer, Gastroenterology, Nov. 2, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29102616;2017
MISCAN-Colon (Erasmus/MSK);Meulen MPV, Kapidzic A, Leerdam MEV, van der Steen A, Kuipers EJ, Spaander MCW, de Koning HJ, Hol L, Lansdorp-Vogelaar I, Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis, Cancer Epidemiol Biomarkers Prev, Aug. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28515110;2017
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ, van Ballegooijen M, Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening, Clin Gastroenterol Hepatol, July 18, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28733262;2017
MISCAN-Colon (Erasmus/MSK);Goede SL, Rabeneck L, van Ballegooijen M, Zauber AG, Paszat LF, Hoch JS, Yong JH, Kroep S, Tinmouth J, Lansdorp-Vogelaar I, Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening, PLoS One, Jan. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28296927;2017
EACMo (MGH);Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, et al., Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis, Clin Gastroenterol Hepatol, Sept. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28089850;2017
EACMo (MGH);Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, et al., Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device, Clin Gastroenterol Hepatol, Sept. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28238953;2017
MISCAN-ESO (Erasmus/UW);Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, et al., Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis, Clin Gastroenterol Hepatol, Sept. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28089850;2017
MISCAN-ESO (Erasmus/UW);Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, et al., Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device, Clin Gastroenterol Hepatol, Sept. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28238953;2017
MSCE-EAC (FHCRC);Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, et al., Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis, Clin Gastroenterol Hepatol, Sept. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28089850;2017
LCOS (Stanford);Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, et al., The impact of overdiagnosis on the selection of efficient lung cancer screening strategies, Int J Cancer, June 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28073150;2017
LCPM (MGH);Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, et al., The impact of overdiagnosis on the selection of efficient lung cancer screening strategies, Int J Cancer, June 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28073150;2017
LCPM (MGH);Sheehan DF, Criss SD, Gazelle GS, Pandharipande PV, Kong CY, Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach, PLoS One, Jan. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28273181;2017
LMO (FHCRC);Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, et al., The impact of overdiagnosis on the selection of efficient lung cancer screening strategies, Int J Cancer, June 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28073150;2017
MISCAN-Lung (Erasmus);Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, et al., The impact of overdiagnosis on the selection of efficient lung cancer screening strategies, Int J Cancer, June 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28073150;2017
SimSmoke (Georgetown);Fleischer NL, Thrasher JF, Reynales-Shigematsu LM, Cummings KM, Meza R, Zhang Y, Levy DT, Mexico SimSmoke: how changes in tobacco control policies would impact smoking prevalence and smoking attributable deaths in Mexico, Glob Public Health, July 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26837721;2017
SimSmoke (Georgetown);Levy DT, Borland R, Villanti AC, Niaura R, Yuan Z, Zhang Y, Meza R, Holford TR, Fong GT, Cummings KM, Abrams DB, et al., The Application of a Decision-Theoretic Model to Estimate the Public Health Impact of Vaporized Nicotine Product Initiation in the United States, Nicotine Tob Res, Feb. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27613952;2017
UM-LCSc (Michigan);Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, et al., The impact of overdiagnosis on the selection of efficient lung cancer screening strategies, Int J Cancer, June 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28073150;2017
UM-LCSc (Michigan);Cherng ST, Tam J, Christine PJ, Meza R, The Authors Respond, Epidemiology, Jan. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27682523;2017
MISCAN-PRO (Erasmus);Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, et al., Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials, Ann Intern Med, Oct. 3, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28869989;2017
MISCAN-PRO (Erasmus);Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R, Is prostate cancer different in black men? Answers from 3 natural history models, Cancer, June 15, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28436011;2017
MISCAN-PRO (Erasmus);de Carvalho TM, Heijnsdijk EAM, de Koning HJ, When should active surveillance for prostate cancer stop if no progression is detected?, Prostate, June 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28419541;2017
MISCAN-PRO (Erasmus);de Carvalho TM, Heijnsdijk EA, de Koning HJ, Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study, BJU Int, April 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27222299;2017
PSAPC (FHCRC);Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, et al., Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials, Ann Intern Med, Oct. 3, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28869989;2017
PSAPC (FHCRC);Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R, Is prostate cancer different in black men? Answers from 3 natural history models, Cancer, June 15, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28436011;2017
PSAPC (FHCRC);Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R, Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms, Cancer Epidemiol Biomarkers Prev, Feb. 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27742670;2017
SCANS (Michigan);Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, et al., Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials, Ann Intern Med, Oct. 3, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28869989;2017
SCANS (Michigan);Tran Q, Kidwell KM, Tsodikov A, A joint model of cancer incidence, metastasis, and mortality, Lifetime Data Anal, Sept. 4, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28871363;2017
SCANS (Michigan);Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R, Is prostate cancer different in black men? Answers from 3 natural history models, Cancer, June 15, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=28436011;2017
SCANS (Michigan);Rice JD, Tsodikov A, Semiparametric time-to-event modeling in the presence of a latent progression event, Biometrics, June 1, 2017 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27556886;2017
Bayesian Simulation Model (MDACC);Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, et al., Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies, Ann Intern Med, Feb. 16, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26756606;2016
BCOS (Stanford);Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, et al., Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies, Ann Intern Med, Feb. 16, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26756606;2016
CISNET-DFCI (Dana-Farber);Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, et al., Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies, Ann Intern Med, Feb. 16, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26756606;2016
MISCAN-Fadia (Erasmus);Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, et al., Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes, Ann Intern Med, Nov. 15, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27548583;2016
MISCAN-Fadia (Erasmus);Miglioretti DL, Lange J, van den Broek JJ, Lee CI, van Ravesteyn NT, Ritley D, Kerlikowske K, Fenton JJ, Melnikow J, de Koning HJ, Hubbard RA, et al., Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study, Ann Intern Med, Feb. 16, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26756460;2016
MISCAN-Fadia (Erasmus);Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, et al., Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies, Ann Intern Med, Feb. 16, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26756606;2016
Spectrum/G-E (Georgetown/Einstein);Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, et al., Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes, Ann Intern Med, Nov. 15, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27548583;2016
Spectrum/G-E (Georgetown/Einstein);Ray GT, Mandelblatt J, Habel LA, Ramsey S, Kushi LH, Li Y, Lieu TA, Breast cancer multigene testing trends and impact on chemotherapy use, Am J Manag Care, May 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27266581;2016
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, et al., Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies, Ann Intern Med, Feb. 16, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26756606;2016
UWBCS (Wisconsin);Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, et al., Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes, Ann Intern Med, Nov. 15, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27548583;2016
UWBCS (Wisconsin);Cevik M, Ergun MA, Stout NK, Trentham-Dietz A, Craven M, Alagoz O, Using Active Learning for Speeding up Calibration in Simulation Models, Med Decis Making, July 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26471190;2016
UWBCS (Wisconsin);Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, et al., Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies, Ann Intern Med, Feb. 16, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26756606;2016
Policy1-Cervix (CCNSW);Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K, Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries, Int J Cancer, Dec. 15, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27541596;2016
Policy1-Cervix (CCNSW);Simms KT, Laprise JF, Smith MA, Lew JB, Caruana M, Brisson M, Canfell K, Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis, Lancet Public Health, Dec. 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=29253419;2016
Policy1-Cervix (CCNSW);Smith MA, Gertig D, Hall M, Simms K, Lew JB, Malloy M, Saville M, Canfell K, Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use, BMC Health Serv Res, April 26, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27112193;2016
Policy1-Cervix (CCNSW);Smith M, Lew JB, Simms K, Canfell K, Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program, Med J Aust, March 21, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26985849;2016
Policy1-Cervix (CCNSW);Lew JB, Simms K, Smith M, Lewis H, Neal H, Canfell K, Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand, PLoS One, Jan. 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27187495;2016
CRC-SPIN (RAND);Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I, Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications, Med Decis Making, July 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26746432;2016
CRC-SPIN (RAND);Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM, Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force, JAMA, June 21, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27305518;2016
MISCAN-Colon (Erasmus/MSK);Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, Dominitz JA, Levin TR, Corley DA, Lansdorp-Vogelaar I, Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test, Clin Gastroenterol Hepatol, Oct. 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27211498;2016
MISCAN-Colon (Erasmus/MSK);Joseph DA, Meester RG, Zauber AG, Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M, Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity, Cancer, Aug. 15, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27200481;2016
MISCAN-Colon (Erasmus/MSK);Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I, Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications, Med Decis Making, July 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26746432;2016
MISCAN-Colon (Erasmus/MSK);van der Steen A, van Rosmalen J, Kroep S, van Hees F, Steyerberg EW, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I, Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria, Med Decis Making, July 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26957567;2016
MISCAN-Colon (Erasmus/MSK);Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM, Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force, JAMA, June 21, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27305518;2016
SimCRC (Minnesota/MGH);Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I, Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications, Med Decis Making, July 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26746432;2016
SimCRC (Minnesota/MGH);Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM, Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force, JAMA, June 21, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27305518;2016
MSCE-EAC (FHCRC);Yankeelov TE, An G, Saut O, Luebeck EG, Popel AS, Ribba B, Vicini P, Zhou X, Weis JA, Ye K, Genin GM, et al., Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success, Ann Biomed Eng, Sept. 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27384942;2016
MSCE-EAC (FHCRC);Curtius K, Wong CJ, Hazelton WD, Kaz AM, Chak A, Willis JE, Grady WM, Luebeck EG, A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus, PLoS Comput Biol, May 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27168458;2016
LCPM (MGH);Tramontano AC, Sheehan DF, McMahon PM, Dowling EC, Holford TR, Ryczak K, Lesko SM, Levy DT, Kong CY, Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study, BMJ Open, Feb. 29, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26928026;2016
MISCAN-Lung (Erasmus);ten Haaf K, de Koning HJ, Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses, JAMA Oncol, Feb. 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26869001;2016
SimSmoke (Georgetown);Levy DT, Yuan Z, Luo Y, Mays D, Seven years of progress in tobacco control: an evaluation of the effect of nations meeting the highest level MPOWER measures between 2007 and 2014, Tob Control, Dec. 12, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27956650;2016
SimSmoke (Georgetown);Levy DT, Mays D, Yuan Z, Hammond D, Thrasher JF, Public health benefits from pictorial health warnings on US cigarette packs: a SimSmoke simulation, Tob Control, Nov. 2, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27807299;2016
SimSmoke (Georgetown);Levy D, Mohlman MK, Zhang Y, Estimating the Potential Impact of Tobacco Control Policies on Adverse Maternal and Child Health Outcomes in the United States Using the SimSmoke Tobacco Control Policy Simulation Model, Nicotine Tob Res, May 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26385929;2016
SimSmoke (Georgetown);Levy DT, Huang AT, Havumaki JS, Meza R, The role of public policies in reducing smoking prevalence: results from the Michigan SimSmoke tobacco policy simulation model, Cancer Causes Control, May 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26983616;2016
SimSmoke (Georgetown);Levy DT, Meza R, Zhang Y, Holford TR, Gauging the Effect of U.S. Tobacco Control Policies From 1965 Through 2014 Using SimSmoke, Am J Prev Med, April 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26673484;2016
SimSmoke (Georgetown);Holford TR, Levy DT, Meza R, Comparison of Smoking History Patterns Among African American and White Cohorts in the United States Born 1890 to 1990, Nicotine Tob Res, April 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26980861;2016
SimSmoke (Georgetown);Levy D, Fergus C, Rudov L, McCormick-Ricket I, Carton T, Tobacco Policies in Louisiana: Recommendations for Future Tobacco Control Investment from SimSmoke, a Policy Simulation Model, Prev Sci, Feb. 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26314867;2016
UM-LCSc (Michigan);Cherng ST, Tam J, Christine PJ, Meza R, Modeling the Effects of E-cigarettes on Smoking Behavior: Implications for Future Adult Smoking Prevalence, Epidemiology, Nov. 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27093020;2016
UM-LCSm (Michigan);Holford TR, Levy DT, Meza R, Comparison of Smoking History Patterns Among African American and White Cohorts in the United States Born 1890 to 1990, Nicotine Tob Res, April 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26980861;2016
YLCM (Yale);Holford TR, Levy DT, Meza R, Comparison of Smoking History Patterns Among African American and White Cohorts in the United States Born 1890 to 1990, Nicotine Tob Res, April 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26980861;2016
MISCAN-PRO (Erasmus);de Carvalho TM, Heijnsdijk EA, de Koning HJ, Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men, Int J Cancer, May 15, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26695380;2016
PSAPC (FHCRC);Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R, Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies, JAMA Oncol, July 1, 2016 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=27010943;2016
Bayesian Simulation Model (MDACC);Mandelblatt J, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout N. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. Writing Committee of the Breast Cancer Working Group  2015 Apr. AHRQ Publication No. 14-05201-EF-4.;;2015
BCOS (Stanford);Mandelblatt J, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout N. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. Writing Committee of the Breast Cancer Working Group  2015 Apr. AHRQ Publication No. 14-05201-EF-4.;;2015
CISNET-DFCI (Dana-Farber);Mandelblatt J, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout N. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. Writing Committee of the Breast Cancer Working Group  2015 Apr. AHRQ Publication No. 14-05201-EF-4.;;2015
MISCAN-Fadia (Erasmus);van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ, Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis, J Natl Cancer Inst, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25948872;2015
MISCAN-Fadia (Erasmus);van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ, et al., Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program, Am J Prev Med, May 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25891052;2015
MISCAN-Fadia (Erasmus);Mandelblatt J, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout N. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. Writing Committee of the Breast Cancer Working Group  2015 Apr. AHRQ Publication No. 14-05201-EF-4.;;2015
MISCAN-Fadia (Erasmus);Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, et al., Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts, Ann Intern Med, Feb. 3, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25486550;2015
Spectrum/G-E (Georgetown/Einstein);van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ, Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis, J Natl Cancer Inst, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25948872;2015
Spectrum/G-E (Georgetown/Einstein);van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ, et al., Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program, Am J Prev Med, May 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25891052;2015
Spectrum/G-E (Georgetown/Einstein);Mandelblatt J, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout N. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. Writing Committee of the Breast Cancer Working Group  2015 Apr. AHRQ Publication No. 14-05201-EF-4.;;2015
UWBCS (Wisconsin);Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK, Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model, Health Rep, Dec. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26676233;2015
UWBCS (Wisconsin);van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ, Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis, J Natl Cancer Inst, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25948872;2015
UWBCS (Wisconsin);Sprague BL, Gangnon RE, Hampton JM, Egan KM, Titus LJ, Kerlikowske K, Remington PL, Newcomb PA, Trentham-Dietz A, Variation in Breast Cancer-Risk Factor Associations by Method of Detection: Results From a Series of Case-Control Studies, Am J Epidemiol, June 15, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25944893;2015
UWBCS (Wisconsin);Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD, et al., Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts, Radiology, March 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25350548;2015
UWBCS (Wisconsin);Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, et al., Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts, Ann Intern Med, Feb. 3, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25486550;2015
UWBCS (Wisconsin);Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD, Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts, Am J Obstet Gynecol, Jan. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24959654;2015
HSPH-Cervical (Harvard);Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, Hunt WC, Waxman A, Wheeler CM, Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis, Ann Intern Med, Oct. 20, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26414147;2015
MISCAN-Colon (Erasmus/MSK);van Hees F, Zauber AG, van Veldhuizen H, Heijnen ML, Penning C, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I, The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands, Gut, Dec. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26063755;2015
MISCAN-Colon (Erasmus/MSK);van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, Zauber AG, van Ballegooijen M, Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness, Gastroenterology, Nov. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26253304;2015
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, Goede SL, Ma J, Xiau-Cheng W, Pawlish K, van Ballegooijen M, Jemal A, State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences, Cancer, Oct. 15, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26150014;2015
MISCAN-Colon (Erasmus/MSK);Henrikson NB, Webber EM, Goddard KA, Scrol A, Piper M, Williams MS, Zallen DT, Calonge N, Ganiats TG, Janssens AC, Zauber A, et al., Family history and the natural history of colorectal cancer: systematic review, Genet Med, Sept. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25590981;2015
MISCAN-Colon (Erasmus/MSK);Goede SL, Rabeneck L, Lansdorp-Vogelaar I, Zauber AG, Paszat LF, Hoch JS, Yong JH, van Hees F, Tinmouth J, van Ballegooijen M, The impact of stratifying by family history in colorectal cancer screening programs, Int J Cancer, Sept. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25663135;2015
MISCAN-Colon (Erasmus/MSK);Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, Jemal A, Lansdorp-Vogelaar I, Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018, Cancer, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25763558;2015
MISCAN-Colon (Erasmus/MSK);Goede SL, Kuntz KM, van Ballegooijen M, Knudsen AB, Lansdorp-Vogelaar I, Tangka FK, Howard DH, Chin J, Zauber AG, Seeff LC, Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening, Med Care, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26067885;2015
MISCAN-Colon (Erasmus/MSK);Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Jensen CD, van der Meulen MP, Levin TR, Quinn VP, Schottinger JE, Zauber AG, Corley DA, van Ballegooijen M, et al., Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model, JAMA, June 16, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26080339;2015
MISCAN-Colon (Erasmus/MSK);Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM, Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection, Int J Cancer, June 15, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25403937;2015
MISCAN-Colon (Erasmus/MSK);van der Steen A, Knudsen AB, van Hees F, Walter GP, Berger FG, Daguise VG, Kuntz KM, Zauber AG, van Ballegooijen M, Lansdorp-Vogelaar I, Optimal colorectal cancer screening in states' low-income, uninsured populationsthe case of South Carolina, Health Serv Res, June 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25324198;2015
MISCAN-Colon (Erasmus/MSK);Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Goede SL, Levin TR, Quinn VP, Ballegooijen Mv, Corley DA, Zauber AG, Colorectal cancer deaths attributable to nonuse of screening in the United States, Ann Epidemiol, March 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25721748;2015
MISCAN-Colon (Erasmus/MSK);Zauber AG, The impact of screening on colorectal cancer mortality and incidence: has it really made a difference?, Dig Dis Sci, March 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25740556;2015
MISCAN-Colon (Erasmus/MSK);Rabeneck L, Horton S, Zauber AG, Earle C. Colorectal Cancer. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Disease Control Priorities. Third Edition. Washington, DC: The World Bank  2015. p. 101-120.;;2015
SimCRC (Minnesota/MGH);Jalal H, Goldhaber-Fiebert JD, Kuntz KM, Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling, Med Decis Making, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25840900;2015
SimCRC (Minnesota/MGH);Goede SL, Kuntz KM, van Ballegooijen M, Knudsen AB, Lansdorp-Vogelaar I, Tangka FK, Howard DH, Chin J, Zauber AG, Seeff LC, Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening, Med Care, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26067885;2015
SimCRC (Minnesota/MGH);Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM, Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection, Int J Cancer, June 15, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25403937;2015
SimCRC (Minnesota/MGH);van der Steen A, Knudsen AB, van Hees F, Walter GP, Berger FG, Daguise VG, Kuntz KM, Zauber AG, van Ballegooijen M, Lansdorp-Vogelaar I, Optimal colorectal cancer screening in states' low-income, uninsured populationsthe case of South Carolina, Health Serv Res, June 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25324198;2015
EACMo (MGH);Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG, The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma, Cancer Epidemiol Biomarkers Prev, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25931440;2015
EACMo (MGH);Hur C, Choi SE, Kong CY, Wang GQ, Xu H, Polydorides AD, Xue LY, Perzan KE, Tramontano AC, Richards-Kortum RR, Anandasabapathy S, et al., High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis, World J Gastroenterol, May 14, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25987774;2015
MISCAN-ESO (Erasmus/UW);Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M, An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling, Gastroenterology, Sept. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25935635;2015
MISCAN-ESO (Erasmus/UW);Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M, The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions, Med Decis Making, Aug. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25277672;2015
MISCAN-ESO (Erasmus/UW);Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG, The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma, Cancer Epidemiol Biomarkers Prev, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25931440;2015
MISCAN-ESO (Erasmus/UW);Inadomi JM, Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus, Best Pract Res Clin Gastroenterol, Feb. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25743456;2015
MSCE-EAC (FHCRC);Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG, The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma, Cancer Epidemiol Biomarkers Prev, July 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25931440;2015
MSCE-EAC (FHCRC);Curtius K, Hazelton WD, Jeon J, Luebeck EG, A Multiscale Model Evaluates Screening for Neoplasia in Barrett's Esophagus, PLoS Comput Biol, May 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26001209;2015
LCPM (MGH);Lowry KP, Gazelle GS, Gilmore ME, Johanson C, Munshi V, Choi SE, Tramontano AC, Kong CY, McMahon PM, Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis, Cancer, May 15, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25652107;2015
LCPM (MGH);Tramontano AC, Schrag DL, Malin JK, Miller MC, Weeks JC, Swan JS, McMahon PM, Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study, Med Decis Making, April 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25670839;2015
MISCAN-Lung (Erasmus);Ten Haaf K, de Koning HJ, Overdiagnosis in lung cancer screening: why modelling is essential, J Epidemiol Community Health, Nov. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26071497;2015
MISCAN-Lung (Erasmus);Ten Haaf K, de Koning HJ, Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?, J Thorac Oncol, Sept. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26287320;2015
MISCAN-Lung (Erasmus);Ten Haaf K, van Rosmalen J, de Koning HJ, Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials, Cancer Epidemiol Biomarkers Prev, Jan. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25312998;2015
SimSmoke (Georgetown);Levy DT, Lindblom EN, Fleischer NL, Thrasher J, Mohlman MK, Zhang Y, Monshouwer K, Nagelhout GE, Public Health Effects of Restricting Retail Tobacco Product Displays and Ads, Tob Regul Sci, April 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26191538;2015
UM-LCSm (Michigan);Meza R, Meernik C, Jeon J, Cote ML, Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010, PLoS One, Jan. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25822850;2015
YLCM (Yale);Oh C, Holford TR, Age-Period-Cohort approaches to back-calculation of cancer incidence rate, Stat Med, May 20, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25715831;2015
MISCAN-PRO (Erasmus);de Carvalho TM, Heijnsdijk EA, de Koning HJ, Screening for prostate cancer in the US? Reduce the harms and keep the benefit, Int J Cancer, April 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25123412;2015
PSAPC (FHCRC);Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, Etzioni R, Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer, Cancer Epidemiol Biomarkers Prev, April 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25613117;2015
SCANS (Michigan);Ha J, Tsodikov A, Semiparametric estimation in the proportional hazard model accounting for a misclassified cause of failure, Biometrics, Dec. 1, 2015 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=26102346;2015
UWBCS (Wisconsin);Mandelblatt J, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout N. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. Writing Committee of the Breast Cancer Working Group  2015 Apr. AHRQ Publication No. 14-05201-EF-4.;;2015
CISNET-DFCI (Dana-Farber);Jia N, Lee SJ. An Exact Formula for Estimation of Age-Specific Sensitivity for Screening Tests. APPL MATH 2014 Oct 5:2771-2778.;;2014
Bayesian Simulation Model (MDACC);Berry DA, Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: application to an article in Cancer, Cancer, Sept. 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24925345;2014
Bayesian Simulation Model (MDACC);Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A, Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status, Epidemiol Rev, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24375928;2014
BCOS (Stanford);Gallaher J, Babu A, Plevritis S, Anderson ARA, Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease, Cancer Res, Jan. 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24408919;2014
CISNET-DFCI (Dana-Farber);Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, et al., Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality, J Natl Cancer Inst, Nov. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25255803;2014
CISNET-DFCI (Dana-Farber);Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, et al., Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography, J Natl Cancer Inst, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24872543;2014
MISCAN-Fadia (Erasmus);Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, et al., Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality, J Natl Cancer Inst, Nov. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25255803;2014
MISCAN-Fadia (Erasmus);Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, et al., Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, Ann Intern Med, July 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25023249;2014
MISCAN-Fadia (Erasmus);Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, et al., Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography, J Natl Cancer Inst, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24872543;2014
Spectrum/G-E (Georgetown/Einstein);Habbema JD, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF, Melnikow J, Kuntz KM, Owens DK, Feuer EJ, Models in the development of clinical practice guidelines, Ann Intern Med, Dec. 2, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25437409;2014
Spectrum/G-E (Georgetown/Einstein);Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, et al., Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality, J Natl Cancer Inst, Nov. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25255803;2014
Spectrum/G-E (Georgetown/Einstein);Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, et al., Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, Ann Intern Med, July 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25023249;2014
Spectrum/G-E (Georgetown/Einstein);Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, et al., Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography, J Natl Cancer Inst, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24872543;2014
Spectrum/G-E (Georgetown/Einstein);Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, Isaacs C, Wood M, McKinnon W, et al., Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer, J Clin Oncol, March 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24449235;2014
UWBCS (Wisconsin);Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, et al., Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality, J Natl Cancer Inst, Nov. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25255803;2014
UWBCS (Wisconsin);Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL, Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010, Obstet Gynecol, Oct. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25198271;2014
UWBCS (Wisconsin);Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL, Prevalence of mammographically dense breasts in the United States, J Natl Cancer Inst, Oct. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25217577;2014
UWBCS (Wisconsin);Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, et al., Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography, J Natl Cancer Inst, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24872543;2014
UWBCS (Wisconsin);Trentham-Dietz A, Sprague BL, Hampton JM, Miglioretti DL, Nelson HD, Titus LJ, Egan KM, Remington PL, Newcomb PA, Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studies, Breast Cancer Res Treat, May 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24647890;2014
UWBCS (Wisconsin);Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A, Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status, Epidemiol Rev, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24375928;2014
HSPH-Cervical (Harvard);Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ, An updated natural history model of cervical cancer: derivation of model parameters, Am J Epidemiol, Sept. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25081182;2014
HSPH-Cervical (Harvard);Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE, The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States, Int J Cancer, Aug. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24226935;2014
Policy1-Cervix (CCNSW);C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J, The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds, Health Technol Assess, April 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24762804;2014
Policy1-Cervix (CCNSW);Smith MA, Canfell K, Testing previous model predictions against new data on human papillomavirus vaccination program outcomes, BMC Res Notes, Feb. 25, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24568634;2014
Policy1-Cervix (CCNSW);Smith MA, Canfell K, Incremental benefits of male HPV vaccination: accounting for inequality in population uptake, PLoS One, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25089637;2014
CRC-SPIN (RAND);Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, et al., Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, Ann Intern Med, July 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25023249;2014
MISCAN-Colon (Erasmus/MSK);Saini SD, van Hees F, Vijan S, Smarter screening for cancer: possibilities and challenges of personalization, JAMA, Dec. 3, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25461993;2014
MISCAN-Colon (Erasmus/MSK);Cenin DR, St John DJ, Ledger MJ, Slevin T, Lansdorp-Vogelaar I, Optimising the expansion of the National Bowel Cancer Screening Program, Med J Aust, Oct. 20, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25332032;2014
MISCAN-Colon (Erasmus/MSK);van Hees F, Zauber AG, Klabunde CN, Goede SL, Lansdorp-Vogelaar I, van Ballegooijen M, The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study, JAMA Intern Med, Oct. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25133641;2014
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, et al., Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, Ann Intern Med, July 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25023249;2014
MISCAN-Colon (Erasmus/MSK);van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis, Ann Intern Med, June 3, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24887616;2014
SimCRC (Minnesota/MGH);Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, et al., Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, Ann Intern Med, July 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25023249;2014
EACMo (MGH);Yasuda K, Choi SE, Nishioka NS, Rattner DW, Puricelli WP, Tramontano AC, Kitano S, Hur C, Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus, Dig Dis Sci, July 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24395382;2014
EACMo (MGH);Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, et al., Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling, Cancer Epidemiol Biomarkers Prev, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24692500;2014
EACMo (MGH);Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C, Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis, Cancer Prev Res (Phila), March 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24380852;2014
MISCAN-ESO (Erasmus/UW);Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, et al., Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling, Cancer Epidemiol Biomarkers Prev, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24692500;2014
MSCE-EAC (FHCRC);Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, et al., Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling, Cancer Epidemiol Biomarkers Prev, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24692500;2014
LCOS (Stanford);de Koning HJ, Meza R, Plevritis SK, Raising the bar for the U.S. Preventive Services Task Force, Ann Intern Med, Oct. 7, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25285549;2014
LCOS (Stanford);Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, et al., Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials, Cancer, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24577803;2014
LCOS (Stanford);de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, et al., Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force, Ann Intern Med, March 4, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24379002;2014
LCOS (Stanford);Gallaher J, Babu A, Plevritis S, Anderson ARA, Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease, Cancer Res, Jan. 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24408919;2014
LCOS (Stanford);McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, et al., Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling, PLoS One, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24979231;2014
LCPM (MGH);Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, et al., Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials, Cancer, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24577803;2014
LCPM (MGH);de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, et al., Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force, Ann Intern Med, March 4, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24379002;2014
LCPM (MGH);McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, et al., Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling, PLoS One, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24979231;2014
LMO (FHCRC);Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, et al., Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials, Cancer, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24577803;2014
LMO (FHCRC);de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, et al., Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force, Ann Intern Med, March 4, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24379002;2014
LMO (FHCRC);McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, et al., Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling, PLoS One, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24979231;2014
MISCAN-Lung (Erasmus);de Koning HJ, Meza R, Plevritis SK, Raising the bar for the U.S. Preventive Services Task Force, Ann Intern Med, Oct. 7, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25285549;2014
MISCAN-Lung (Erasmus);Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, et al., Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials, Cancer, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24577803;2014
MISCAN-Lung (Erasmus);de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, et al., Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force, Ann Intern Med, March 4, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24379002;2014
MISCAN-Lung (Erasmus);McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, et al., Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling, PLoS One, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24979231;2014
SimSmoke (Georgetown);Near AM, Blackman K, Currie LM, Levy DT, Sweden SimSmoke: the effect of tobacco control policies on smoking and snus prevalence and attributable deaths, Eur J Public Health, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24287030;2014
SimSmoke (Georgetown);Holford TR, Meza R, Warner KE, Meernik C, Jeon J, Moolgavkar SH, Levy DT, Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012, JAMA, Jan. 8, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24399555;2014
SimSmoke (Georgetown);Holford TR, Levy DT, McKay LA, Clarke L, Racine B, Meza R, Land S, Jeon J, Feuer EJ. Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med 2014 46(2):e31-7.;;2014
SimSmoke (Georgetown);Levy DT, Huang AT, Currie LM, Clancy L, The benefits from complying with the framework convention on tobacco control: a SimSmoke analysis of 15 European nations, Health Policy Plan, Dec. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24262281;2014
SimSmoke (Georgetown);Maslennikova GY, Oganov RG, Boytsov SA, Ross H, Huang AT, Near A, Kotov A, Berezhnova I, Levy DT, Russia SimSmoke: the long-term effects of tobacco control policies on smoking prevalence and smoking-attributable deaths in Russia, Tob Control, Nov. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23853252;2014
UM-LCSc (Michigan);de Koning HJ, Meza R, Plevritis SK, Raising the bar for the U.S. Preventive Services Task Force, Ann Intern Med, Oct. 7, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25285549;2014
UM-LCSc (Michigan);Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, et al., Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials, Cancer, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24577803;2014
UM-LCSc (Michigan);de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, et al., Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force, Ann Intern Med, March 4, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24379002;2014
UM-LCSc (Michigan);McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, et al., Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling, PLoS One, Jan. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24979231;2014
UM-LCSm (Michigan);Holford TR, Meza R, Warner KE, Meernik C, Jeon J, Moolgavkar SH, Levy DT, Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012, JAMA, Jan. 8, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24399555;2014
UM-LCSm (Michigan);Holford TR, Levy DT, McKay LA, Clarke L, Racine B, Meza R, Land S, Jeon J, Feuer EJ. Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med 2014 46(2):e31-7.;;2014
YLCM (Yale);Holford TR, Meza R, Warner KE, Meernik C, Jeon J, Moolgavkar SH, Levy DT, Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012, JAMA, Jan. 8, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24399555;2014
YLCM (Yale);Holford TR, Levy DT, McKay LA, Clarke L, Racine B, Meza R, Land S, Jeon J, Feuer EJ. Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med 2014 46(2):e31-7.;;2014
MISCAN-PRO (Erasmus);Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, et al., Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, Ann Intern Med, July 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25023249;2014
MISCAN-PRO (Erasmus);Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H, et al., Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen, BMC Med, Feb. 11, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24512643;2014
PSAPC (FHCRC);Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR, Expected population impacts of discontinued prostate-specific antigen screening, Cancer, Nov. 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25065910;2014
PSAPC (FHCRC);Etzioni R, Gulati R, Oversimplifying overdiagnosis, J Gen Intern Med, Sept. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24830739;2014
PSAPC (FHCRC);Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S, Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada, Int J Cancer, Aug. 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24443367;2014
PSAPC (FHCRC);Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, et al., Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits, Ann Intern Med, July 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25023249;2014
PSAPC (FHCRC);Etzioni RD, Thompson IM, What do the screening trials really tell us and where do we go from here?, Urol Clin North Am, May 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24725484;2014
PSAPC (FHCRC);Etzioni R, Gulati R, RE: A model too far, J Natl Cancer Inst, April 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24659791;2014
PSAPC (FHCRC);Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R, Individualized estimates of overdiagnosis in screen-detected prostate cancer, J Natl Cancer Inst, Feb. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24399850;2014
SCANS (Michigan);Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR, Expected population impacts of discontinued prostate-specific antigen screening, Cancer, Nov. 15, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=25065910;2014
SCANS (Michigan);Hu C, Tsodikov A, Joint modeling approach for semicompeting risks data with missing nonterminal event status, Lifetime Data Anal, Oct. 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24430204;2014
SCANS (Michigan);Hu C, Tsodikov A, Semiparametric regression analysis for time-to-event marked endpoints in cancer studies, Biostatistics, July 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24379192;2014
SCANS (Michigan);Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA, Prostate cancer in young men: an important clinical entity, Nat Rev Urol, June 1, 2014 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24818853;2014
Bayesian Simulation Model (MDACC);Berry DA, Breast cancer screening: controversy of impact, Breast, Aug. 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24074796;2013
Bayesian Simulation Model (MDACC);Luo S, Yi M, Huang X, Hunt KK, A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer, Stat Med, June 15, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22996169;2013
BCOS (Stanford);Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW, Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers, Fam Cancer, March 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23086584;2013
MISCAN-Fadia (Erasmus);van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens, Eur J Cancer, Nov. 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23871248;2013
MISCAN-Fadia (Erasmus);Mandelblatt J, van Ravesteyn N, Schechter C, Chang Y, Huang AT, Near AM, de Koning H, Jemal A, Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention, Cancer, July 15, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23625540;2013
MISCAN-Fadia (Erasmus);Mandelblatt JS, Tosteson AN, van Ravesteyn NT, Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control, JAMA Intern Med, Feb. 11, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23303388;2013
Spectrum/G-E (Georgetown/Einstein);Mandelblatt J, van Ravesteyn N, Schechter C, Chang Y, Huang AT, Near AM, de Koning H, Jemal A, Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention, Cancer, July 15, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23625540;2013
Spectrum/G-E (Georgetown/Einstein);Etzioni R, Gulati R, Mallinger L, Mandelblatt J, Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening, Ann Intern Med, June 4, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23732716;2013
Spectrum/G-E (Georgetown/Einstein);Braithwaite D, Mandelblatt JS, Kerlikowske K, To screen or not to screen older women for breast cancer: a conundrum, Future Oncol, June 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23718292;2013
Spectrum/G-E (Georgetown/Einstein);Braithwaite D, Zhu W, Hubbard RA, O'Meara ES, Miglioretti DL, Geller B, Dittus K, Moore D, Wernli KJ, Mandelblatt J, Kerlikowske K, et al., Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates?, J Natl Cancer Inst, March 6, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23385442;2013
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Tosteson AN, van Ravesteyn NT, Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control, JAMA Intern Med, Feb. 11, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23303388;2013
UWBCS (Wisconsin);Batina NG, Trentham-Dietz A, Gangnon RE, Sprague BL, Rosenberg MA, Stout NK, Fryback DG, Alagoz O, Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis, Breast Cancer Res Treat, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23417335;2013
HSPH-Cervical (Harvard);Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK, Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results, J Low Genit Tract Dis, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23519303;2013
UMN-Cervical (Minnesota);Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER, Screening for cervical cancer: a modeling study for the US Preventive Services Task Force, J Low Genit Tract Dis, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23519288;2013
CRC-SPIN (RAND);Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D, Secular trends in colon and rectal cancer relative survival, J Natl Cancer Inst, Dec. 4, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24174654;2013
CRC-SPIN (RAND);Hubbard RA, Johnson E, Hsia R, Rutter CM, The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening, Cancer Epidemiol Biomarkers Prev, Sept. 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23868091;2013
CRC-SPIN (RAND);Wernli KJ, Rutter CM, Dachman AH, Zafar HM, Suspected extracolonic neoplasms detected on CT colonography: literature review and possible outcomes, Acad Radiol, June 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23465379;2013
MISCAN-Colon (Erasmus/MSK);Cho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, Mariotto AB, Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies, Ann Intern Med, Nov. 19, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24247672;2013
MISCAN-Colon (Erasmus/MSK);Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, Kuipers EJ, van Leerdam ME, van Ballegooijen M, Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening, Gut, May 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22490518;2013
MISCAN-Colon (Erasmus/MSK);O'Mahony JF, van Rosmalen J, Zauber AG, van Ballegooijen M, Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information, Med Decis Making, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22927697;2013
MISCAN-Colon (Erasmus/MSK);Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I, Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality, J Natl Cancer Inst Monogr, Jan. 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23962515;2013
SimCRC (Minnesota/MGH);Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D, Secular trends in colon and rectal cancer relative survival, J Natl Cancer Inst, Dec. 4, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24174654;2013
EACMo (MGH);Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ, Trends in esophageal adenocarcinoma incidence and mortality, Cancer, March 15, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23303625;2013
LCPM (MGH);Munshi V, McMahon P, Importance of Smoking Cessation in a Lung Cancer Screening Program, Curr Surg Rep, Dec. 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=24312745;2013
LCPM (MGH);Tramontano AC, Cipriano LE, Kong CY, Shepard JA, Lanuti M, Gazelle GS, McMahon PM, Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer, AJR Am J Roentgenol, May 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23617484;2013
SimSmoke (Georgetown);Levy DT, Ellis JA, Mays D, Huang AT, Smoking-related deaths averted due to three years of policy progress, Bull World Health Organ, July 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23825878;2013
SimSmoke (Georgetown);Levy DT, Currie L, Clancy L, Tobacco control policy in the UK: blueprint for the rest of Europe?, Eur J Public Health, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22826505;2013
SimSmoke (Georgetown);Levy DT, Blackman K, Currie LM, Mons U, Germany SimSmoke: the effect of tobacco control policies on future smoking prevalence and smoking-attributable deaths in Germany, Nicotine Tob Res, Feb. 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22855886;2013
PSAPC (FHCRC);Etzioni R, Gulati R, Mallinger L, Mandelblatt J, Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening, Ann Intern Med, June 4, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23732716;2013
PSAPC (FHCRC);Etzioni RD, Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development, Evid Based Med, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22773765;2013
PSAPC (FHCRC);Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM, Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening, Med Care, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23269114;2013
PSAPC (FHCRC);Etzioni R, Gulati R, Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence, Med Care, April 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23481032;2013
PSAPC (FHCRC);Gulati R, Gore JL, Etzioni R, Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms, Ann Intern Med, Feb. 5, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23381039;2013
PSAPC (FHCRC);Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I, Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality, J Natl Cancer Inst Monogr, Jan. 1, 2013 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23962515;2013
Bayesian Simulation Model (MDACC);Bekele BN, Nieto-Barajas LE, Munsell MF. Analysis of partially incomplete tables of breast cancer patients' characteristics with an ordinal variable. Journal of Statistical Theory and Practice 2012 9:725-44.;;2012
BCOS (Stanford);Sigal BM, Munoz DF, Kurian AW, Plevritis SK, A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers, Cancer Epidemiol Biomarkers Prev, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22556274;2012
BCOS (Stanford);Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK, Online tool to guide decisions for BRCA1/2 mutation carriers, J Clin Oncol, Feb. 10, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22231042;2012
BCOS (Stanford);Lin RS, Plevritis SK, Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model, Cancer Causes Control, Jan. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22116537;2012
CISNET-DFCI (Dana-Farber);van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, et al., Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk, Ann Intern Med, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22547470;2012
MISCAN-Fadia (Erasmus);van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, et al., Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk, Ann Intern Med, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22547470;2012
MISCAN-Fadia (Erasmus);Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, et al., Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis, Ann Intern Med, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22547473;2012
Spectrum/G-E (Georgetown/Einstein);Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, Levy D, de Koning HJ, Mandelblatt JS, Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality, Breast Cancer Res Treat, Dec. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23104221;2012
Spectrum/G-E (Georgetown/Einstein);Mandelblatt J, Schechter C, Levy D, Zauber A, Chang Y, Etzioni R, Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions, Med Decis Making, Sept. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22990079;2012
Spectrum/G-E (Georgetown/Einstein);van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, et al., Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk, Ann Intern Med, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22547470;2012
Spectrum/G-E (Georgetown/Einstein);Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, et al., Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis, Ann Intern Med, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22547473;2012
Spectrum/G-E (Georgetown/Einstein);Morrissey JP, Lich KH, Price RA, Mandelblatt J, Computational modeling and multilevel cancer control interventions, J Natl Cancer Inst Monogr, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22623597;2012
Spectrum/G-E (Georgetown/Einstein);Near AM, Mandelblatt JS, Schechter CB, Stoto MA, Using Simulation Modeling to Inform Strategies to Reduce Breast Cancer Mortality in Black Women in the District of Columbia, Epidemiol Res Int, April 26, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23914301;2012
UWBCS (Wisconsin);Sprague BL, Trentham-Dietz A, Cronin KA, A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010, Obstet Gynecol, Sept. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22914469;2012
UWBCS (Wisconsin);van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, et al., Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk, Ann Intern Med, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22547470;2012
UWBCS (Wisconsin);Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, et al., Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis, Ann Intern Med, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22547473;2012
UWBCS (Wisconsin);Gangnon RE, Sprague B, Stout N, Alagoz O, Trentham-Dietz A. Age-period-cohort analysis of invasive breast cancer incidence in the United States, 1935-2008. Proceedings of 45th Annual SEER Meeting  June 27-30, 2012  2012. p. S6.;;2012
UWBCS (Wisconsin);Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Am J Epidemiol 2012 173(Suppl 11):S135.;;2012
Policy1-Cervix (CCNSW);Lew JB, Howard K, Gertig D, Smith M, Clements M, Nickson C, Shi JF, Dyer S, Lord S, Creighton P, Kang YJ, et al., Expenditure and resource utilisation for cervical screening in Australia, BMC Health Serv Res, Dec. 5, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23216968;2012
Policy1-Cervix (CCNSW);Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J, Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer, Vaccine, Nov. 20, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23199969;2012
Policy1-Cervix (CCNSW);Legood R, Smith M, Lew JB, Walker R, Moss S, Kitchener H, Patnick J, Canfell K, Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study, BMJ, Oct. 31, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23117060;2012
CRC-SPIN (RAND);Zheng W, Rutter CM, Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer, Cancer Epidemiol Biomarkers Prev, Oct. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22911331;2012
CRC-SPIN (RAND);Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DS, Adverse events after screening and follow-up colonoscopy, Cancer Causes Control, Feb. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22105578;2012
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A, Contribution of screening and survival differences to racial disparities in colorectal cancer rates, Cancer Epidemiol Biomarkers Prev, May 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22514249;2012
MISCAN-Colon (Erasmus/MSK);Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, et al., Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths, N Engl J Med, Feb. 23, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22356322;2012
SimCRC (Minnesota/MGH);Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM, Rescreening of persons with a negative colonoscopy result: results from a microsimulation model, Ann Intern Med, Nov. 6, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23128861;2012
SimCRC (Minnesota/MGH);Haug U, Knudsen AB, Kuntz KM, How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis, Int J Cancer, Nov. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22307927;2012
EACMo (MGH);Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM, The cost effectiveness of radiofrequency ablation for Barrett's esophagus, Gastroenterology, Sept. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22626608;2012
EACMo (MGH);Omer ZB, Ananthakrishnan AN, Nattinger KJ, Cole EB, Lin JJ, Kong CY, Hur C, Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis, Clin Gastroenterol Hepatol, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22426086;2012
EACMo (MGH);Choi SE, Hur C, Screening and surveillance for Barrett's esophagus: current issues and future directions, Curr Opin Gastroenterol, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22508325;2012
MISCAN-ESO (Erasmus/UW);Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM, The cost effectiveness of radiofrequency ablation for Barrett's esophagus, Gastroenterology, Sept. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22626608;2012
LCPM (MGH);Feuer EJ, Moolgavkar SH, Levy DT, Kimmel M, Clarke LD. The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network (CISNET). Risk Anal 2012 Aug 7 32(S1):S1-S201.;;2012
LCPM (MGH);Bloch M, Backinger CL, Compton WM, Conway K, Standing on the threshold of change, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882881;2012
LCPM (MGH);McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, Cipriano LE, Bouzan C, Gazelle GS, Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882882;2012
LCPM (MGH);Anderson CM, Burns DM, Dodd KW, Feuer EJ, Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882884;2012
LCPM (MGH);Boer R, Moolgavkar SH, Levy DT, Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000--summary and limitations, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882889;2012
LCPM (MGH);Rosenberg MA, Feuer EJ, Yu B, Sun J, Henley SJ, Shanks TG, Anderson CM, McMahon PM, Thun MJ, Burns DM, Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882890;2012
LCPM (MGH);Holford TR, Clark L, Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882891;2012
LCPM (MGH);Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT, Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882892;2012
LCPM (MGH);Feuer EJ, Levy DT, McCarthy WJ, Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882893;2012
LCPM (MGH);Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, et al., Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000, J Natl Cancer Inst, April 4, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22423009;2012
LCPM (MGH);Kong CY, Lee JM, McMahon PM, Lowry KP, Omer ZB, Eisenberg JD, Pandharipande PV, Gazelle GS, Using radiation risk models in cancer screening simulations: important assumptions and effects on outcome projections, Radiology, March 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22357897;2012
LMO (FHCRC);Hazelton WD, Goodman G, Rom WN, Tockman M, Thornquist M, Moolgavkar S, Weissfeld JL, Feng Z, Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers, Math Biosci, Nov. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22705252;2012
MISCAN-Lung (Erasmus);Feuer EJ, Moolgavkar SH, Levy DT, Kimmel M, Clarke LD. The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network (CISNET). Risk Anal 2012 Aug 7 32(S1):S1-S201.;;2012
MISCAN-Lung (Erasmus);Bloch M, Backinger CL, Compton WM, Conway K, Standing on the threshold of change, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882881;2012
MISCAN-Lung (Erasmus);Anderson CM, Burns DM, Dodd KW, Feuer EJ, Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882884;2012
MISCAN-Lung (Erasmus);Boer R, Moolgavkar SH, Levy DT, Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000--summary and limitations, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882889;2012
MISCAN-Lung (Erasmus);Rosenberg MA, Feuer EJ, Yu B, Sun J, Henley SJ, Shanks TG, Anderson CM, McMahon PM, Thun MJ, Burns DM, Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882890;2012
MISCAN-Lung (Erasmus);Holford TR, Clark L, Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882891;2012
MISCAN-Lung (Erasmus);Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT, Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882892;2012
MISCAN-Lung (Erasmus);Feuer EJ, Levy DT, McCarthy WJ, Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882893;2012
MISCAN-Lung (Erasmus);Schultz FW, Boer R, de Koning HJ, Chapter 7: Description of MISCAN-lung, the Erasmus MC Lung Cancer microsimulation model for evaluating cancer control interventions, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882895;2012
MISCAN-Lung (Erasmus);Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, et al., Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000, J Natl Cancer Inst, April 4, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22423009;2012
SimSmoke (Georgetown);Feuer EJ, Moolgavkar SH, Levy DT, Kimmel M, Clarke LD. The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network (CISNET). Risk Anal 2012 Aug 7 32(S1):S1-S201.;;2012
SimSmoke (Georgetown);Bloch M, Backinger CL, Compton WM, Conway K, Standing on the threshold of change, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882881;2012
SimSmoke (Georgetown);Levy DT, Blackman K, Zaloshnja E, Chapter 10: A macro-model of smoking and lung cancer: examining aggregate trends in lung cancer rates using the CPS-I and CPS-II and two-stage clonal expansion models, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882883;2012
SimSmoke (Georgetown);Anderson CM, Burns DM, Dodd KW, Feuer EJ, Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882884;2012
SimSmoke (Georgetown);Holford TR, Levy DT, Chapter 14: Comparing the adequacy of carcinogenesis models in estimating U.S. population rates for lung cancer mortality, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882888;2012
SimSmoke (Georgetown);Boer R, Moolgavkar SH, Levy DT, Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000--summary and limitations, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882889;2012
SimSmoke (Georgetown);Rosenberg MA, Feuer EJ, Yu B, Sun J, Henley SJ, Shanks TG, Anderson CM, McMahon PM, Thun MJ, Burns DM, Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882890;2012
SimSmoke (Georgetown);Holford TR, Clark L, Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882891;2012
SimSmoke (Georgetown);Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT, Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882892;2012
SimSmoke (Georgetown);Feuer EJ, Levy DT, McCarthy WJ, Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882893;2012
SimSmoke (Georgetown);Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, et al., Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000, J Natl Cancer Inst, April 4, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22423009;2012
SimSmoke (Georgetown);Levy DT, Boyle RG, Abrams DB, The role of public policies in reducing smoking: the Minnesota SimSmoke tobacco policy model, Am J Prev Med, Nov. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23079215;2012
SimSmoke (Georgetown);Carreras G, Gorini G, Gallus S, Iannucci L, Levy DT, Predicting the future prevalence of cigarette smoking in Italy over the next three decades, Eur J Public Health, Oct. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21893504;2012
SimSmoke (Georgetown);Levy D, Gallus S, Blackman K, Carreras G, La Vecchia C, Gorini G, Italy SimSmoke: the effect of tobacco control policies on smoking prevalence and smoking attributable deaths in Italy, BMC Public Health, Aug. 29, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22931428;2012
SimSmoke (Georgetown);Levy DT, Blackman K, Currie LM, Levy J, Clancy L, SimSmokeFinn: how far can tobacco control policies move Finland toward tobacco-free 2040 goals?, Scand J Public Health, Aug. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22899560;2012
SimSmoke (Georgetown);Katanoda K, Levy DT, Nakamura M, Hagimoto A, Oshima A, Modeling the effect of disseminating brief intervention for smoking cessation at medical facilities in Japan: a simulation study, Cancer Causes Control, June 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22527171;2012
SimSmoke (Georgetown);Nagelhout GE, Levy DT, Blackman K, Currie L, Clancy L, Willemsen MC, The effect of tobacco control policies on smoking prevalence and smoking-attributable deaths. Findings from the Netherlands SimSmoke Tobacco Control Policy Simulation Model, Addiction, Feb. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21906197;2012
SimSmoke (Georgetown);Levy D, de Almeida LM, Szklo A, The Brazil SimSmoke policy simulation model: the effect of strong tobacco control policies on smoking prevalence and smoking-attributable deaths in a middle income nation, PLoS Med, Jan. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=23139643;2012
UM-LCSm (Michigan);Feuer EJ, Moolgavkar SH, Levy DT, Kimmel M, Clarke LD. The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network (CISNET). Risk Anal 2012 Aug 7 32(S1):S1-S201.;;2012
UM-LCSm (Michigan);Bloch M, Backinger CL, Compton WM, Conway K, Standing on the threshold of change, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882881;2012
UM-LCSm (Michigan);Anderson CM, Burns DM, Dodd KW, Feuer EJ, Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882884;2012
UM-LCSm (Michigan);Boer R, Moolgavkar SH, Levy DT, Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000--summary and limitations, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882889;2012
UM-LCSm (Michigan);Rosenberg MA, Feuer EJ, Yu B, Sun J, Henley SJ, Shanks TG, Anderson CM, McMahon PM, Thun MJ, Burns DM, Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882890;2012
UM-LCSm (Michigan);Holford TR, Clark L, Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882891;2012
UM-LCSm (Michigan);Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT, Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882892;2012
UM-LCSm (Michigan);Feuer EJ, Levy DT, McCarthy WJ, Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882893;2012
UM-LCSm (Michigan);McCarthy WJ, Meza R, Jeon J, Moolgavkar SH, Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882894;2012
UM-LCSm (Michigan);Hazelton WD, Jeon J, Meza R, Moolgavkar SH, Chapter 8: The FHCRC lung cancer model, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882896;2012
UM-LCSm (Michigan);Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, et al., Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000, J Natl Cancer Inst, April 4, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22423009;2012
YLCM (Yale);Feuer EJ, Moolgavkar SH, Levy DT, Kimmel M, Clarke LD. The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network (CISNET). Risk Anal 2012 Aug 7 32(S1):S1-S201.;;2012
YLCM (Yale);Bloch M, Backinger CL, Compton WM, Conway K, Standing on the threshold of change, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882881;2012
YLCM (Yale);Anderson CM, Burns DM, Dodd KW, Feuer EJ, Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882884;2012
YLCM (Yale);Holford TR, Levy DT, Chapter 14: Comparing the adequacy of carcinogenesis models in estimating U.S. population rates for lung cancer mortality, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882888;2012
YLCM (Yale);Boer R, Moolgavkar SH, Levy DT, Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000--summary and limitations, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882889;2012
YLCM (Yale);Rosenberg MA, Feuer EJ, Yu B, Sun J, Henley SJ, Shanks TG, Anderson CM, McMahon PM, Thun MJ, Burns DM, Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882890;2012
YLCM (Yale);Holford TR, Clark L, Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882891;2012
YLCM (Yale);Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT, Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882892;2012
YLCM (Yale);Feuer EJ, Levy DT, McCarthy WJ, Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem, Risk Anal, July 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22882893;2012
YLCM (Yale);Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, et al., Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000, J Natl Cancer Inst, April 4, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22423009;2012
MISCAN-PRO (Erasmus);Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB, et al., The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines, Cancer, Dec. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22605665;2012
MISCAN-PRO (Erasmus);Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R, The impact of PLCO control arm contamination on perceived PSA screening efficacy, Cancer Causes Control, June 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22488488;2012
PSAPC (FHCRC);Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB, et al., The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines, Cancer, Dec. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22605665;2012
PSAPC (FHCRC);Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R, The impact of PLCO control arm contamination on perceived PSA screening efficacy, Cancer Causes Control, June 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22488488;2012
SCANS (Michigan);Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB, et al., The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines, Cancer, Dec. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22605665;2012
SCANS (Michigan);Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R, The impact of PLCO control arm contamination on perceived PSA screening efficacy, Cancer Causes Control, June 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22488488;2012
SCANS (Michigan);Ha J, Tsodikov A, Isotonic estimation of survival under a misattribution of cause of death, Lifetime Data Anal, Jan. 1, 2012 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22094534;2012
Bayesian Simulation Model (MDACC);Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, et al., Modeling the impact of population screening on breast cancer mortality in the United States, Breast, Oct. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22015298;2011
BCOS (Stanford);Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, et al., Modeling the impact of population screening on breast cancer mortality in the United States, Breast, Oct. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22015298;2011
CISNET-DFCI (Dana-Farber);Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, et al., Modeling the impact of population screening on breast cancer mortality in the United States, Breast, Oct. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22015298;2011
MISCAN-Fadia (Erasmus);Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, et al., Modeling the impact of population screening on breast cancer mortality in the United States, Breast, Oct. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22015298;2011
MISCAN-Fadia (Erasmus);Edwards-Bennett SM, Racial disparities in breast cancer mortality--letter, Cancer Epidemiol Biomarkers Prev, May 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21546367;2011
MISCAN-Fadia (Erasmus);van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS, Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States, Cancer Epidemiol Biomarkers Prev, Jan. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21119071;2011
Spectrum/G-E (Georgetown/Einstein);Mandelblatt J, Cronin K, Response to Hendrick and Helvie by the Cancer Intervention Surveillance Modeling Network (CISNET) Breast Working Group, AJR Am J Roentgenol, Oct. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21940561;2011
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, et al., Modeling the impact of population screening on breast cancer mortality in the United States, Breast, Oct. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22015298;2011
Spectrum/G-E (Georgetown/Einstein);van Ravesteyn NT, Heijnsdijk EA, Draisma G, de Koning HJ, Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals, Br J Cancer, Sept. 27, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21863031;2011
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Stout N, Trentham-Dietz A, To screen or not to screen women in their 40s for breast cancer: is personalized risk-based screening the answer?, Ann Intern Med, July 5, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21727294;2011
Spectrum/G-E (Georgetown/Einstein);Edwards-Bennett SM, Racial disparities in breast cancer mortality--letter, Cancer Epidemiol Biomarkers Prev, May 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21546367;2011
Spectrum/G-E (Georgetown/Einstein);van Ravesteyn NT, Heijnsdijk EA, de Koning HJ, More on screening mammography, N Engl J Med, Jan. 20, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21247323;2011
Spectrum/G-E (Georgetown/Einstein);van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS, Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States, Cancer Epidemiol Biomarkers Prev, Jan. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21119071;2011
UWBCS (Wisconsin);Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, et al., Modeling the impact of population screening on breast cancer mortality in the United States, Breast, Oct. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22015298;2011
UWBCS (Wisconsin);Mandelblatt JS, Stout N, Trentham-Dietz A, To screen or not to screen women in their 40s for breast cancer: is personalized risk-based screening the answer?, Ann Intern Med, July 5, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21727294;2011
UWBCS (Wisconsin);Sprague BL, Trentham-Dietz A, Hampton JM, Egan KM, Titus-Ernstof L, Remington PL, Newcomb PA. Variation in breast cancer risk factors by mode of detection. Am J Epidemiol 2011 173(Suppl 11):S251.;;2011
HSPH-Cervical (Harvard);Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE, Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice, Lancet Oncol, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21684207;2011
MISCAN-STDSIM (Erasmus);Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D, et al., Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study, Lancet, March 12, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21367446;2011
Policy1-Cervix (CCNSW);Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K, The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia, Vaccine, Nov. 8, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21419773;2011
Policy1-Cervix (CCNSW);Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, Simonella L, Ma L, Kang YJ, Zhang YZ, Smith MA, et al., Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study, BMC Cancer, June 13, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21668946;2011
Policy1-Cervix (CCNSW);Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF, Legood R, Smith MA, Nickson C, Qiao YL, et al., Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies, Vaccine, March 16, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21211586;2011
CRC-SPIN (RAND);Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, et al., Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations, Radiology, Nov. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21813740;2011
CRC-SPIN (RAND);Rutter CM, Miglioretti DL, Savarino JE, Evaluating risk factor assumptions: a simulation-based approach, BMC Med Inform Decis Mak, Sept. 7, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21899767;2011
CRC-SPIN (RAND);Rutter CM, Knudsen AB, Pandharipande PV, Computer disease simulation models: integrating evidence for health policy, Acad Radiol, Sept. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21435924;2011
CRC-SPIN (RAND);Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG, A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression, Med Decis Making, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21673186;2011
CRC-SPIN (RAND);van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM, Clarifying differences in natural history between models of screening: the case of colorectal cancer, Med Decis Making, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21673187;2011
CRC-SPIN (RAND);Rutter CM, Zaslavsky AM, Feuer EJ, Dynamic microsimulation models for health outcomes: a review, Med Decis Making, Jan. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20484091;2011
CRC-SPIN (RAND);Lansdorp-Vogelaar I, Knudsen AB, Brenner H, Cost-effectiveness of colorectal cancer screening, Epidemiol Rev, Jan. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21633092;2011
MISCAN-Colon (Erasmus/MSK);Wilschut JA, Hol L, Dekker E, Jansen JB, Van Leerdam ME, Lansdorp-Vogelaar I, Kuipers EJ, Habbema JD, Van Ballegooijen M, Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening, Gastroenterology, Nov. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21784045;2011
MISCAN-Colon (Erasmus/MSK);Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, et al., Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations, Radiology, Nov. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21813740;2011
MISCAN-Colon (Erasmus/MSK);Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JD, van Ballegooijen M, How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?, Cancer, Sept. 15, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21387272;2011
MISCAN-Colon (Erasmus/MSK);Bradley CJ, Lansdorp-Vogelaar I, Yabroff KR, Dahman B, Mariotto A, Feuer EJ, Brown ML, Productivity savings from colorectal cancer prevention and control strategies, Am J Prev Med, Aug. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21767717;2011
MISCAN-Colon (Erasmus/MSK);Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG, A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression, Med Decis Making, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21673186;2011
MISCAN-Colon (Erasmus/MSK);van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM, Clarifying differences in natural history between models of screening: the case of colorectal cancer, Med Decis Making, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21673187;2011
MISCAN-Colon (Erasmus/MSK);Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A, State disparities in colorectal cancer mortality patterns in the United States, Cancer Epidemiol Biomarkers Prev, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21737410;2011
MISCAN-Colon (Erasmus/MSK);Stock C, Knudsen AB, Lansdorp-Vogelaar I, Haug U, Brenner H, Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy, Gastrointest Endosc, March 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21353840;2011
SimCRC (Minnesota/MGH);Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, et al., Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations, Radiology, Nov. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21813740;2011
SimCRC (Minnesota/MGH);Rutter CM, Knudsen AB, Pandharipande PV, Computer disease simulation models: integrating evidence for health policy, Acad Radiol, Sept. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21435924;2011
SimCRC (Minnesota/MGH);Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG, A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression, Med Decis Making, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21673186;2011
SimCRC (Minnesota/MGH);van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM, Clarifying differences in natural history between models of screening: the case of colorectal cancer, Med Decis Making, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21673187;2011
SimCRC (Minnesota/MGH);Haug U, Knudsen AB, Brenner H, Kuntz KM, Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review, Expert Rev Mol Diagn, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21745014;2011
SimCRC (Minnesota/MGH);Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H, Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia, Br J Cancer, May 24, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21559011;2011
SimCRC (Minnesota/MGH);Stock C, Knudsen AB, Lansdorp-Vogelaar I, Haug U, Brenner H, Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy, Gastrointest Endosc, March 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21353840;2011
SimCRC (Minnesota/MGH);Lansdorp-Vogelaar I, Knudsen AB, Brenner H, Cost-effectiveness of colorectal cancer screening, Epidemiol Rev, Jan. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21633092;2011
EACMo (MGH);Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, McMahon PM, Gazelle GS, Hur C, The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model, Cancer Epidemiol Biomarkers Prev, Nov. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21930957;2011
MSCE-EAC (FHCRC);Hazelton WD, Luebeck EG, Biomarker-based early cancer detection: is it achievable?, Sci Transl Med, Nov. 16, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22089449;2011
LCPM (MGH);McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, Johnson BE, Weeks JC, Gazelle GS, Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, Nov. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21892105;2011
LMO (FHCRC);Hazelton WD, Luebeck EG, Biomarker-based early cancer detection: is it achievable?, Sci Transl Med, Nov. 16, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22089449;2011
MISCAN-Lung (Erasmus);Shi L, Tian H, McCarthy WJ, Berman B, Wu S, Boer R, Exploring the uncertainties of early detection results: model-based interpretation of mayo lung project, BMC Cancer, March 7, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21375784;2011
SimSmoke (Georgetown);Levy DT, Pearson JL, Villanti AC, Blackman K, Vallone DM, Niaura RS, Abrams DB, Modeling the future effects of a menthol ban on smoking prevalence and smoking-attributable deaths in the United States, Am J Public Health, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21566034;2011
MISCAN-PRO (Erasmus);Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ, How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening, Med Decis Making, July 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21406620;2011
MISCAN-PRO (Erasmus);Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R, et al., What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models, Cancer Epidemiol Biomarkers Prev, May 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21546365;2011
PSAPC (FHCRC);Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R, Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates, J Clin Epidemiol, Dec. 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=22032753;2011
PSAPC (FHCRC);Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R, et al., What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models, Cancer Epidemiol Biomarkers Prev, May 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21546365;2011
SCANS (Michigan);Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R, et al., What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models, Cancer Epidemiol Biomarkers Prev, May 1, 2011 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21546365;2011
BCOS (Stanford);Bailey SL, Sigal BM, Plevritis SK, A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years, J Natl Cancer Inst, Aug. 18, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20664027;2010
BCOS (Stanford);Kurian AW, Sigal BM, Plevritis SK, Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers, J Clin Oncol, Jan. 10, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19996031;2010
CISNET-DFCI (Dana-Farber);Weedon-Fekjaer H, Tretli S, Aalen OO, Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening, Stat Methods Med Res, Oct. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20356856;2010
CISNET-DFCI (Dana-Farber);Kalager M, Zelen M, Langmark F, Adami HO, Effect of screening mammography on breast-cancer mortality in Norway, N Engl J Med, Sept. 23, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20860502;2010
MISCAN-STDSIM (Erasmus);Lonky NM, Mahdavi A, Wolde-Tsadik G, Bajamundi K, Felix JC, Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience, J Low Genit Tract Dis, July 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20592555;2010
Policy1-Cervix (CCNSW);Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, Lord S, Canfell K, Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years, BMC Public Health, Nov. 26, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21110881;2010
UMN-Cervical (Minnesota);Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF, Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness, Obstet Gynecol, Nov. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20966702;2010
CRC-SPIN (RAND);Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG, Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population, J Natl Cancer Inst, Aug. 18, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20664028;2010
CRC-SPIN (RAND);Rutter CM, Savarino JE, An evidence-based microsimulation model for colorectal cancer: validation and application, Cancer Epidemiol Biomarkers Prev, Aug. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20647403;2010
MISCAN-Colon (Erasmus/MSK);Zauber AG, van Ballegooijen M, Petitti D, Lansdorp-Vogelaar I, United States Preventive Services Task Force recommendations: age to end screening misunderstood, Dis Colon Rectum, Oct. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20847630;2010
MISCAN-Colon (Erasmus/MSK);Zauber AG, Cost-effectiveness of colonoscopy, Gastrointest Endosc Clin N Am, Oct. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20889076;2010
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M, Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis, Ann Intern Med, Sept. 21, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20855801;2010
MISCAN-Colon (Erasmus/MSK);Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG, Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population, J Natl Cancer Inst, Aug. 18, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20664028;2010
MISCAN-Colon (Erasmus/MSK);van Ballegooijen M, Boer R, Zauber AG, Simulation of colorectal cancer screening: what we do and do not know and does it matter, Best Pract Res Clin Gastroenterol, Aug. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20833347;2010
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, Knudsen AB, Brenner H, Cost-effectiveness of colorectal cancer screening - an overview, Best Pract Res Clin Gastroenterol, Aug. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20833348;2010
MISCAN-Colon (Erasmus/MSK);Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, et al., Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates, Cancer, Feb. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19998273;2010
SimCRC (Minnesota/MGH);Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M, Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis, Ann Intern Med, Sept. 21, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20855801;2010
SimCRC (Minnesota/MGH);Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG, Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population, J Natl Cancer Inst, Aug. 18, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20664028;2010
SimCRC (Minnesota/MGH);Lansdorp-Vogelaar I, Knudsen AB, Brenner H, Cost-effectiveness of colorectal cancer screening - an overview, Best Pract Res Clin Gastroenterol, Aug. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20833348;2010
EACMo (MGH);Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C, The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data, Dis Esophagus, Aug. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20353441;2010
EACMo (MGH);Hur C, Hayeck TJ, Yeh JM, Richards EM, Spechler SJ, Gazelle GS, Kong CY, Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma, PLoS One, March 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20208996;2010
SimSmoke (Georgetown);Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB, Exploring scenarios to dramatically reduce smoking prevalence: a simulation model of the three-part cessation process, Am J Public Health, July 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20466969;2010
SimSmoke (Georgetown);Abrams DB, Graham AL, Levy DT, Mabry PL, Orleans CT, Boosting population quits through evidence-based cessation treatment and policy, Am J Prev Med, March 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20176308;2010
SimSmoke (Georgetown);Levy DT, Graham AL, Mabry PL, Abrams DB, Orleans CT, Modeling the impact of smoking-cessation treatment policies on quit rates, Am J Prev Med, March 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20176309;2010
SimSmoke (Georgetown);Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB, Reaching Healthy People 2010 by 2013: A SimSmoke simulation, Am J Prev Med, March 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20176310;2010
SimSmoke (Georgetown);Zaloshnja E, Ross H, Levy DT, The impact of tobacco control policies in Albania, Tob Control, Dec. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20679417;2010
SimSmoke (Georgetown);Tauras JA, Levy D, Chaloupka FJ, Villanti A, Niaura RS, Vallone D, Abrams DB, Menthol and non-menthol smoking: the impact of prices and smoke-free air laws, Addiction, Dec. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=21059142;2010
SimSmoke (Georgetown);Levy DT, Cho SI, Kim YM, Park S, Suh MK, Kam S, SimSmoke model evaluation of the effect of tobacco control policies in Korea: the unknown success story, Am J Public Health, July 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20466968;2010
MISCAN-PRO (Erasmus);Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ, Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam, J Natl Cancer Inst, March 3, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20142584;2010
PSAPC (FHCRC);Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R, Calibrating disease progression models using population data: a critical precursor to policy development in cancer control, Biostatistics, Oct. 1, 2010 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20530126;2010
Bayesian Simulation Model (MDACC);Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, et al., Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms, Ann Intern Med, Nov. 17, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19920274;2009
BCOS (Stanford);Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, et al., Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms, Ann Intern Med, Nov. 17, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19920274;2009
CISNET-DFCI (Dana-Farber);Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, et al., Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms, Ann Intern Med, Nov. 17, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19920274;2009
CISNET-DFCI (Dana-Farber);Rue M, Vilaprinyo E, Lee S, Martinez-Alonso M, Carles MD, Marcos-Gragera R, Pla R, Espinas JA, Effectiveness of early detection on breast cancer mortality reduction in Catalonia (Spain), BMC Cancer, Sept. 15, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19754959;2009
MISCAN-Fadia (Erasmus);Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, et al., Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms, Ann Intern Med, Nov. 17, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19920274;2009
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, et al., Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms, Ann Intern Med, Nov. 17, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19920274;2009
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Silliman R, Hanging in the balance: making decisions about the benefits and harms of breast cancer screening among the oldest old without a safety net of scientific evidence, J Clin Oncol, Feb. 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19075258;2009
UWBCS (Wisconsin);Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, et al., Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms, Ann Intern Med, Nov. 17, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19920274;2009
HSPH-Cervical (Harvard);Kim JJ, Goldie SJ, Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States, BMJ, Oct. 8, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19815582;2009
CRC-SPIN (RAND);Rutter CM, Miglioretti DL, Savarino JE, Bayesian Calibration of Microsimulation Models, J Am Stat Assoc, Dec. 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=20076767;2009
CRC-SPIN (RAND);Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM. Cost-effectiveness of CT Colonography to screen for colorectal cancer. 2009 Jan 22. Available at http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id58TA.pdf.;http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id58TA.pdf;2009
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ, Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening, J Natl Cancer Inst, Oct. 21, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19779203;2009
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ, Habbema JD, Individualizing colonoscopy screening by sex and race, Gastrointest Endosc, July 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19467539;2009
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD, A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials, Cancer, June 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19288570;2009
MISCAN-Colon (Erasmus/MSK);Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD, At what costs will screening with CT colonography be competitive? A cost-effectiveness approach, Int J Cancer, March 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19048626;2009
MISCAN-Colon (Erasmus/MSK);Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM. Cost-effectiveness of CT Colonography to screen for colorectal cancer. 2009 Jan 22. Available at http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id58TA.pdf.;http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id58TA.pdf;2009
SimCRC (Minnesota/MGH);Bentley TG, Weinstein MC, Kuntz KM, Effects of categorizing continuous variables in decision-analytic models, Med Decis Making, Sept. 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19596867;2009
SimCRC (Minnesota/MGH);Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM. Cost-effectiveness of CT Colonography to screen for colorectal cancer. 2009 Jan 22. Available at http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id58TA.pdf.;http://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id58TA.pdf;2009
LCOS (Stanford);Pashkevich MA, Sigal BM, Plevritis SK, Modeling the transition of lung cancer from early to advanced stage, Cancer Causes Control, Nov. 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19629730;2009
LCPM (MGH);Kong CY, McMahon PM, Gazelle GS, Calibration of disease simulation model using an engineering approach, Value Health, June 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19900254;2009
MISCAN-PRO (Erasmus);Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H, Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context, J Natl Cancer Inst, March 18, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19276453;2009
PSAPC (FHCRC);Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H, Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context, J Natl Cancer Inst, March 18, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19276453;2009
PSAPC (FHCRC);Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R, Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States, Cancer Epidemiol Biomarkers Prev, March 1, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19258479;2009
SCANS (Michigan);Chefo S, Tsodikov A, Stage-specific cancer incidence: an artificially mixed multinomial logit model, Stat Med, July 10, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19452568;2009
SCANS (Michigan);Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H, Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context, J Natl Cancer Inst, March 18, 2009 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19276453;2009
CISNET-DFCI (Dana-Farber);Lee SJ, Zelen M, Mortality modeling of early detection programs, Biometrics, June 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17725809;2008
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Potosky AL, On the road to improving the quality of breast cancer care: a distance still to travel, Med Care, Aug. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18665054;2008
UWBCS (Wisconsin);Stout NK, Goldie SJ, Keeping the noise down: common random numbers for disease simulation modeling, Health Care Manag Sci, Dec. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18998599;2008
UWBCS (Wisconsin);Tosteson AN, Stout NK, Fryback DG, Acharyya S, Herman BA, Hannah LG, Pisano ED, Cost-effectiveness of digital mammography breast cancer screening, Ann Intern Med, Jan. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18166758;2008
HSPH-Cervical (Harvard);Kim JJ, Goldie SJ, Health and economic implications of HPV vaccination in the United States, N Engl J Med, Aug. 21, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18716299;2008
MISCAN-STDSIM (Erasmus);Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, Ning L, Killeen J, Kamemoto L, Hernandez BY, Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study, Cancer Res, Nov. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18974124;2008
MISCAN-STDSIM (Erasmus);Trottier H, Mahmud S, Prado JC, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL, Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination, J Infect Dis, May 15, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18419547;2008
MISCAN-STDSIM (Erasmus);Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, Bekkers RL, Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands, PLoS One, Jan. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=19011683;2008
Policy1-Cervix (CCNSW);Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV, The predicted impact of vaccination on human papillomavirus infections in Australia, Int J Cancer, Oct. 15, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18636563;2008
Policy1-Cervix (CCNSW);Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J, Liquid compared with conventional cervical cytology: a systematic review and meta-analysis, Obstet Gynecol, Jan. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18165406;2008
MISCAN-Colon (Erasmus/MSK);Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM, Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force, Ann Intern Med, Nov. 4, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18838717;2008
LCPM (MGH);McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, Weeks JC, Gazelle GS, Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period, Cancer, Dec. 15, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18988293;2008
LCPM (MGH);McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, Shepard JA, Swensen SJ, Gazelle GS, Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study, Radiology, July 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18458247;2008
SimSmoke (Georgetown);Levy DT, Tworek C, Hahn EJ, Davis RE, The Kentucky SimSmoke tobacco policy simulation model: reaching Healthy People 2010 goals through policy change, South Med J, May 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18414175;2008
SimSmoke (Georgetown);Levy DT, Benjakul S, Ross H, Ritthiphakdee B, The role of tobacco control policies in reducing smoking and deaths in a middle income nation: results from the Thailand SimSmoke simulation model, Tob Control, Feb. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18218810;2008
UM-LCSm (Michigan);Meza R, Hazelton WD, Colditz GA, Moolgavkar SH, Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model, Cancer Causes Control, April 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18058248;2008
PSAPC (FHCRC);Etzioni R, Gulati R, Falcon S, Penson DF, Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach, Med Decis Making, May 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18319508;2008
PSAPC (FHCRC);Etzioni R, Feuer E, Studies of prostate-cancer mortality: caution advised, Lancet Oncol, May 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18452850;2008
PSAPC (FHCRC);Inoue LY, Etzioni R, Morrell C, Muller P. Modeling disease progression with longitudinal markers. J Am Stat Assoc 2008 Mar 103(481):259-70.;;2008
PSAPC (FHCRC);Telesca D, Etzioni R, Gulati R, Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends, Biometrics, March 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17501937;2008
PSAPC (FHCRC);Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E, et al., Quantifying the role of PSA screening in the US prostate cancer mortality decline, Cancer Causes Control, March 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18027095;2008
SCANS (Michigan);Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E, et al., Quantifying the role of PSA screening in the US prostate cancer mortality decline, Cancer Causes Control, March 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18027095;2008
SCANS (Michigan);Tsodikov A, Chefo S, Generalized Self-Consistency: Multinomial logit model and Poisson likelihood, J Stat Plan Inference, Jan. 1, 2008 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18709183;2008
Bayesian Simulation Model (MDACC);Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA, The decrease in breast-cancer incidence in 2003 in the United States, N Engl J Med, April 19, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17442911;2007
BCOS (Stanford);Plevritis SK, Salzman P, Sigal BM, Glynn PW, A natural history model of stage progression applied to breast cancer, Stat Med, Feb. 10, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16598706;2007
UW-Cervical (UWash);French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett GP, Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland, Br J Cancer, Feb. 12, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17245341;2007
HSPH-Cervical (Harvard);Kim JJ, Andres-Beck B, Goldie SJ, The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting, Br J Cancer, Nov. 5, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17923869;2007
HSPH-Cervical (Harvard);Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ, Multiparameter calibration of a natural history model of cervical cancer, Am J Epidemiol, July 15, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17526866;2007
MISCAN-STDSIM (Erasmus);Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, Snijders PJ, Meijer CJ, Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months, Int J Cancer, July 15, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17354241;2007
MISCAN-STDSIM (Erasmus);Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA, Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive, Cell Oncol, Jan. 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17429138;2007
UMN-Cervical (Minnesota);Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G, A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program, Sex Health, Sept. 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17931529;2007
CRC-SPIN (RAND);Rutter CM, Yu O, Miglioretti DL, A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts, Stat Med, Jan. 15, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16372387;2007
MISCAN-Colon (Erasmus/MSK);Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007 Dec 20. Available at http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=52.;http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=52;2007
SimCRC (Minnesota/MGH);Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007 Dec 20. Available at http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=52.;http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=52;2007
SimSmoke (Georgetown);Levy DT, Mumford EA, Gerlowski DA, Examining trends in quantity smoked, Nicotine Tob Res, Dec. 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=18058347;2007
SimSmoke (Georgetown);Levy DT, Hyland A, Higbee C, Remer L, Compton C, The role of public policies in reducing smoking prevalence in California: results from the California tobacco policy simulation model, Health Policy, July 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17055104;2007
SimSmoke (Georgetown);Levy DT. The role of public policies in reducing smoking prevalence: results from the SimSmoke tobacco policy simulation model. In: Bonnie RJ, Stratton K, Wallace RB, editors. Committee on Reducing Tobacco Use: Strategies, Barriers, and Consequences, Ending the Tobacco Problem: A Blueprint for the Nation. Washington, DC: Institute of Medicine  2007. p. 578-98.;;2007
SimSmoke (Georgetown);Levy DT, Ross H, Powell L, Bauer JE, Lee HR, The role of public policies in reducing smoking prevalence and deaths caused by smoking in Arizona: results from the Arizona tobacco policy simulation model, J Public Health Manag Pract, Jan. 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17149101;2007
SimSmoke (Georgetown);Ferrante D, Levy D, Peruga A, Compton C, Romano E, The role of public policies in reducing smoking prevalence and deaths: the Argentina Tobacco Policy Simulation Model, Rev Panam Salud Publica, Jan. 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17439692;2007
PSAPC (FHCRC);Mariotto AB, Etzioni R, Krapcho M, Feuer EJ, Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey, Cancer, May 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17372918;2007
PSAPC (FHCRC);Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL, Trends in treatment costs for localized prostate cancer: the healthy screenee effect, Med Care, Feb. 1, 2007 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17224778;2007
Bayesian Simulation Model (MDACC);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst Monographs 2006 36:1-126.;;2006
Bayesian Simulation Model (MDACC);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive summary. J Natl Cancer Inst Monograph 2006 36:1-2.;;2006
Bayesian Simulation Model (MDACC);Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF, Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032892;2006
Bayesian Simulation Model (MDACC);Cronin KA, Feuer EJ, Clarke LD, Plevritis SK, Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032901;2006
BCOS (Stanford);Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM, Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging, JAMA, May 24, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16720823;2006
BCOS (Stanford);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive summary. J Natl Cancer Inst Monograph 2006 36:1-2.;;2006
BCOS (Stanford);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst Monographs 2006 36:1-126.;;2006
BCOS (Stanford);Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P, A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032898;2006
BCOS (Stanford);Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ, A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032899;2006
BCOS (Stanford);Cronin KA, Feuer EJ, Clarke LD, Plevritis SK, Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032901;2006
CISNET-DFCI (Dana-Farber);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive summary. J Natl Cancer Inst Monograph 2006 36:1-2.;;2006
CISNET-DFCI (Dana-Farber);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst Monographs 2006 36:1-126.;;2006
CISNET-DFCI (Dana-Farber);Lee S, Zelen M, A stochastic model for predicting the mortality of breast cancer, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032897;2006
CISNET-DFCI (Dana-Farber);Cronin KA, Feuer EJ, Clarke LD, Plevritis SK, Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032901;2006
MISCAN-Fadia (Erasmus);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive summary. J Natl Cancer Inst Monograph 2006 36:1-2.;;2006
MISCAN-Fadia (Erasmus);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst Monographs 2006 36:1-126.;;2006
MISCAN-Fadia (Erasmus);Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD, The MISCAN-Fadia continuous tumor growth model for breast cancer, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032895;2006
MISCAN-Fadia (Erasmus);Habbema JD, Tan SY, Cronin KA, Impact of mammography on U.S. breast cancer mortality, 1975-2000: are intermediate outcome measures informative?, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032900;2006
MISCAN-Fadia (Erasmus);Cronin KA, Feuer EJ, Clarke LD, Plevritis SK, Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032901;2006
MISCAN-Fadia (Erasmus);Habbema JD, Schechter CB, Cronin KA, Clarke LD, Feuer EJ, Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032902;2006
Spectrum/G-E (Georgetown/Einstein);Liang W, Kasman D, Wang JH, Yuan EH, Mandelblatt JS, Communication between older women and physicians: preliminary implications for satisfaction and intention to have mammography, Patient Educ Couns, Dec. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16872797;2006
Spectrum/G-E (Georgetown/Einstein);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst Monographs 2006 36:1-126.;;2006
Spectrum/G-E (Georgetown/Einstein);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive summary. J Natl Cancer Inst Monograph 2006 36:1-2.;;2006
Spectrum/G-E (Georgetown/Einstein);Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J, The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032894;2006
Spectrum/G-E (Georgetown/Einstein);Cronin KA, Feuer EJ, Clarke LD, Plevritis SK, Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032901;2006
Spectrum/G-E (Georgetown/Einstein);Habbema JD, Schechter CB, Cronin KA, Clarke LD, Feuer EJ, Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032902;2006
UWBCS (Wisconsin);Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG, Retrospective cost-effectiveness analysis of screening mammography, J Natl Cancer Inst, June 7, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16757702;2006
UWBCS (Wisconsin);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive summary. J Natl Cancer Inst Monograph 2006 36:1-2.;;2006
UWBCS (Wisconsin);Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The impact of mammography and adjuvant therapy on U.S. breast cancer mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. J Natl Cancer Inst Monographs 2006 36:1-126.;;2006
UWBCS (Wisconsin);Rosenberg MA, Competing risks to breast cancer mortality, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032889;2006
UWBCS (Wisconsin);Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL, The Wisconsin Breast Cancer Epidemiology Simulation Model, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032893;2006
UWBCS (Wisconsin);Cronin KA, Feuer EJ, Clarke LD, Plevritis SK, Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis, J Natl Cancer Inst Monogr, Jan. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17032901;2006
UW-Cervical (UWash);Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP, Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses, PLoS Med, May 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16573364;2006
MISCAN-STDSIM (Erasmus);Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, et al., Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial, Lancet Oncol, July 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16814206;2006
Policy1-Cervix (CCNSW);Lehtinen M, Herrero R, Mayaud P, Barnabas R, Dillner J, Paavonen J, Smith PG, Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries, Vaccine, Aug. 31, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16950012;2006
MISCAN-Colon (Erasmus/MSK);Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG, How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment, Cancer, Oct. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16933324;2006
SimSmoke (Georgetown);Levy DT, Mumford EA, Compton C, Tobacco control policies and smoking in a population of low education women, 1992-2002, J Epidemiol Community Health, Sept. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=17708007;2006
SimSmoke (Georgetown);Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino GA, Hyland A, Sweanor D, Warner KE, Compton C, The potential impact of a low-nitrosamine smokeless tobacco product on cigarette smoking in the United States: estimates of a panel of experts, Addict Behav, July 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16256276;2006
SimSmoke (Georgetown);Levy DT, Bauer JE, Lee HR, Simulation modeling and tobacco control: creating more robust public health policies, Am J Public Health, March 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16449585;2006
SimSmoke (Georgetown);Levy DT, Bales S, Lam NT, Nikolayev L, The role of public policies in reducing smoking and deaths caused by smoking in Vietnam: results from the Vietnam tobacco policy simulation model, Soc Sci Med, April 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16182422;2006
YLCM (Yale);Holford TR, Approaches to fitting age-period-cohort models with unequal intervals, Stat Med, March 30, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16143994;2006
PSAPC (FHCRC);Zeliadt SB, Potosky AL, Penson DF, Etzioni R, Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer, Int J Radiat Oncol Biol Phys, Oct. 1, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16904843;2006
SCANS (Michigan);Tsodikov A, Szabo A, Wegelin J, A population model of prostate cancer incidence, Stat Med, Aug. 30, 2006 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16397859;2006
Bayesian Simulation Model (MDACC);Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, Oct. 27, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16251534;2005
Bayesian Simulation Model (MDACC);Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA, Role of detection method in predicting breast cancer survival: analysis of randomized screening trials, J Natl Cancer Inst, Aug. 17, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16106024;2005
BCOS (Stanford);Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, Oct. 27, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16251534;2005
BCOS (Stanford);Rosenberg J, Chia YL, Plevritis S, The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database, Breast Cancer Res Treat, Jan. 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15666196;2005
CISNET-DFCI (Dana-Farber);Zelen M, Risks of cancer and families, J Natl Cancer Inst, Nov. 2, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16264169;2005
CISNET-DFCI (Dana-Farber);Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, Oct. 27, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16251534;2005
CISNET-DFCI (Dana-Farber);Shen Y, Zelen M, Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution, Biostatistics, Oct. 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15860542;2005
MISCAN-Fadia (Erasmus);Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, Oct. 27, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16251534;2005
Spectrum/G-E (Georgetown/Einstein);Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, Oct. 27, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16251534;2005
Spectrum/G-E (Georgetown/Einstein);Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt J, Challenges in systematic reviews of economic analyses, Ann Intern Med, June 21, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15968032;2005
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Extermann M, Fox S, Orosz G, Silliman R, Cullen J, Balducci L, et al., Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status, J Gen Intern Med, June 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15987322;2005
UWBCS (Wisconsin);Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, Oct. 27, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16251534;2005
SimSmoke (Georgetown);Levy DT, Nikolayev L, Mumford E, Recent trends in smoking and the role of public policies: results from the SimSmoke tobacco control policy simulation model, Addiction, Oct. 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=16185214;2005
SimSmoke (Georgetown);Levy DT, Nikolayev L, Mumford E, Compton C, The Healthy People 2010 smoking prevalence and tobacco control objectives: results from the SimSmoke tobacco control policy simulation model (United States), Cancer Causes Control, May 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15953978;2005
SimSmoke (Georgetown);Levy DT, Wen CP, Chen TY, Oblak M, Increasing taxes to reduce smoking prevalence and smoking attributable mortality in Taiwan: results from a tobacco policy simulation model, Tob Control, June 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15923449;2005
UM-LCSm (Michigan);Clements MS, Armstrong BK, Moolgavkar SH, Lung cancer rate predictions using generalized additive models, Biostatistics, Oct. 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15860544;2005
UM-LCSm (Michigan);Hazelton WD, Clements MS, Moolgavkar SH, Multistage carcinogenesis and lung cancer mortality in three cohorts, Cancer Epidemiol Biomarkers Prev, May 1, 2005 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15894668;2005
BCOS (Stanford);Chia YL, Salzman P, Plevritis SK, Glynn PW, Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration, Stat Methods Med Res, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15587436;2004
BCOS (Stanford);Boer R, Plevritis S, Clarke L, Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups, Stat Methods Med Res, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15587437;2004
CISNET-DFCI (Dana-Farber);Lee S, Huang H, Zelen M, Early detection of disease and scheduling of screening examinations, Stat Methods Med Res, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15587433;2004
CISNET-DFCI (Dana-Farber);Hu P, Zelen M, Planning of randomized early detection trials, Stat Methods Med Res, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15587435;2004
CISNET-DFCI (Dana-Farber);Zelen M, Forward and backward recurrence times and length biased sampling: age specific models, Lifetime Data Anal, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15690988;2004
CISNET-DFCI (Dana-Farber);Davidov O, Zelen M, Overdiagnosis in early detection programs, Biostatistics, Oct. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15475422;2004
MISCAN-Fadia (Erasmus);Feuer EJ, Boer R, Holford TR. Developing and comparing population models for the early detection of cancer. Stat Meth Med Res Dec 2004 13(6):419-20.;;2004
MISCAN-Fadia (Erasmus);Boer R, Plevritis S, Clarke L, Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups, Stat Methods Med Res, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15587437;2004
Spectrum/G-E (Georgetown/Einstein);Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Muennig P, Chavez Y, Cullen J, Fahs M, Benefits and costs of interventions to improve breast cancer outcomes in African American women, J Clin Oncol, July 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15173213;2004
UWBCS (Wisconsin);Andersen LD, Remington PL, Trentham-Dietz A, Robert S, Community trends in the early detection of breast cancer in Wisconsin, 1980-1998, Am J Prev Med, Jan. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=14700713;2004
MISCAN-STDSIM (Erasmus);Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, et al., POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women, Int J Cancer, May 20, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15054873;2004
Policy1-Cervix (CCNSW);Canfell K, Barnabas R, Patnick J, Beral V, The predicted effect of changes in cervical screening practice in the UK: results from a modelling study, Br J Cancer, Aug. 2, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15266332;2004
MISCAN-Lung (Erasmus);Feuer EJ, Boer R, Holford TR. Developing and comparing population models for the early detection of cancer. Stat Meth Med Res Dec 2004 13(6):419-20.;;2004
SimSmoke (Georgetown);Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, Sweanor D, Warner KE, The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts, Cancer Epidemiol Biomarkers Prev, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15598758;2004
SimSmoke (Georgetown);Levy DT, Chaloupka F, Gitchell J, The effects of tobacco control policies on smoking rates: a tobacco control scorecard, J Public Health Manag Pract, July 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15235381;2004
YLCM (Yale);Feuer EJ, Boer R, Holford TR. Developing and comparing population models for the early detection of cancer. Stat Meth Med Res Dec 2004 13(6):419-20.;;2004
PSAPC (FHCRC);Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ, An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States, Am J Epidemiol, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15561985;2004
PSAPC (FHCRC);Feuer EJ, Etzioni R, Cronin KA, Mariotto A, The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing, Stat Methods Med Res, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15587432;2004
PSAPC (FHCRC);Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF, Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999, Urology, Dec. 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15596192;2004
PSAPC (FHCRC);Inoue LY, Etzioni R, Slate EH, Morrell C, Penson DF, Combining longitudinal studies of PSA, Biostatistics, July 1, 2004 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=15208207;2004
CISNET-DFCI (Dana-Farber);Lee SJ, Zelen M, Modelling the early detection of breast cancer, Ann Oncol, Aug. 1, 2003 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12881377;2003
CISNET-DFCI (Dana-Farber);Davidov O, Zelen M, The theory of case-control studies for early detection programs, Biostatistics, July 1, 2003 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12925508;2003
MISCAN-Fadia (Erasmus);Tan SYGL, van Oortmarssen GJ, Piersma N. Estimating parameters of a microsimulation model for breast cancer screening using the score function method. Ann Oper Res 2003 Mar 119(43):43-61.;;2003
Spectrum/G-E (Georgetown/Einstein);Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, Klein J, Helfand M, The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force, Ann Intern Med, Nov. 18, 2003 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=14623621;2003
Spectrum/G-E (Georgetown/Einstein);Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J, Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results, Med Care Res Rev, Sept. 1, 2003 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12971231;2003
Spectrum/G-E (Georgetown/Einstein);Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA, Hadley J, Schulman KA, Economic evaluation of breast cancer treatment: considering the value of patient choice, J Clin Oncol, March 15, 2003 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12637482;2003
MISCAN-Colon (Erasmus/MSK);van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. 2003 Aug. Available at http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=20.;http://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=20;2003
PSAPC (FHCRC);Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD, Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis, Cancer, Aug. 1, 2003 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12879465;2003
CISNET-DFCI (Dana-Farber);Hu P, Zelen M, Experimental design issues for the early detection of disease: novel designs, Biostatistics, Sept. 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12933599;2002
CISNET-DFCI (Dana-Farber);Parmigiani G, Skates S, Zelen M, Modeling and optimization in early detection programs with a single exam, Biometrics, March 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11890325;2002
CISNET-DFCI (Dana-Farber);Zelen M, Lee SJ, Models and the early detection of disease: methodological considerations, Cancer Treat Res, Jan. 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12613347;2002
CISNET-DFCI (Dana-Farber);Lee SJ, Zelen M, Statistical models for screening: planning public health programs, Cancer Treat Res, Jan. 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12613348;2002
SimSmoke (Georgetown);Levy DT, Chaloupka F, Gitchell J, Mendez D, Warner KE, The use of simulation models for the surveillance, justification and understanding of tobacco control policies, Health Care Manag Sci, April 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11993746;2002
SimSmoke (Georgetown);Levy DT, Friend K, Examining the effects of tobacco treatment policies on smoking rates and smoking related deaths using the SimSmoke computer simulation model, Tob Control, March 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11891368;2002
SimSmoke (Georgetown);Levy DT, Friend K, A simulation model of policies directed at treating tobacco use and dependence, Med Decis Making, Jan. 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11833665;2002
UM-LCSm (Michigan);Gregori G, Hanin L, Luebeck G, Moolgavkar S, Yakovlev A, Testing goodness of fit for stochastic models of carcinogenesis, Math Biosci, Jan. 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11779625;2002
PSAPC (FHCRC);Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ, Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends, J Natl Cancer Inst, July 3, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=12096083;2002
PSAPC (FHCRC);Etzioni R, Berry KM, Legler JM, Shaw P, Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998, Urology, Feb. 1, 2002 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11834397;2002
CISNET-DFCI (Dana-Farber);Shen Y, Wu D, Zelen M, Testing the independence of two diagnostic tests, Biometrics, Dec. 1, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11764239;2001
CISNET-DFCI (Dana-Farber);Shen Y, Zelen M, Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations, J Clin Oncol, Aug. 1, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11481355;2001
Spectrum/G-E (Georgetown/Einstein);Yabroff KR, O'Malley A, Mangan P, Mandelblatt J, Inreach and outreach interventions to improve mammography use, J Am Med Womens Assoc (1972), Sept. 1, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11759785;2001
Spectrum/G-E (Georgetown/Einstein);Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS, The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services, Am J Prev Med, April 1, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11306230;2001
MISCAN-STDSIM (Erasmus);Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ, Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear, Lancet, Nov. 24, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11734239;2001
SimSmoke (Georgetown);Levy DT, Friend K, Polishchuk E, Effect of clean indoor air laws on smokers: the clean air module of the SimSmoke computer simulation model, Tob Control, Dec. 1, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11740026;2001
SimSmoke (Georgetown);Levy DT, Friend K, Holder H, Carmona M, Effect of policies directed at youth access to smoking: results from the SimSmoke computer simulation model, Tob Control, June 1, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11387530;2001
SimSmoke (Georgetown);Levy DT, Friend K, A computer simulation model of mass media interventions directed at tobacco use, Prev Med, March 1, 2001 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11277686;2001
UW-Cervical (UWash);Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB, Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis, Am J Epidemiol, June 15, 2000 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=10905528;2000
SimSmoke (Georgetown);Levy DT, Friend KB, A simulation model of tobacco youth access policies, J Health Polit Policy Law, Dec. 1, 2000 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=11142051;2000
SimSmoke (Georgetown);Levy DT, Cummings KM, Hyland A, Increasing taxes as a strategy to reduce cigarette use and deaths: results of a simulation model, Prev Med, Sept. 1, 2000 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=10964642;2000
SimSmoke (Georgetown);Levy DT, Cummings KM, Hyland A, A simulation of the effects of youth initiation policies on overall cigarette use, Am J Public Health, Aug. 1, 2000 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=10937017;2000
UW-Cervical (UWash);Garnett GP, Anderson RM, Sexually transmitted diseases and sexual behavior: insights from mathematical models, J Infect Dis, Oct. 1, 1996 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=8843245;1996
MISCAN-STDSIM (Erasmus);van Oortmarssen GJ, Habbema JD, Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears, Int J Epidemiol, April 1, 1995 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=7635589;1995
UW-Cervical (UWash);Miller DK, Homan SM, Determining transition probabilities: confusion and suggestions, Med Decis Making, Jan. 1, 1994 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=8152357;1994
YLCM (Yale);Holford TR, Zhang Z, McKay LA, Estimating age, period and cohort effects using the multistage model for cancer, Stat Med, Jan. 15, 1994 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=9061838;1994
YLCM (Yale);Holford TR, Analysing the temporal effects of age, period and cohort, Stat Methods Med Res, Jan. 1, 1992 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=1341663;1992
YLCM (Yale);Holford TR, Understanding the effects of age, period, and cohort on incidence and mortality rates, Annu Rev Public Health, Jan. 1, 1991 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=2049144;1991
MISCAN-STDSIM (Erasmus);[No authors listed] Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes, Br Med J (Clin Res Ed), Sept. 13, 1986 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=3092971;1986
YLCM (Yale);Holford TR, The estimation of age, period and cohort effects for vital rates, Biometrics, June 1, 1983 [Abstract];http://www.ncbi.nlm.nih.gov/pubmed/?term=6626659;1983
